Morphology-based classification of sickle cell disease and βthalassemia using a low-cost automated microscope and machine learning

Pranav Shrestha* , Hendrik Lohse^{4,2}, Christopher Bhatla⁹, Heather McCartney⁴, Alaa Alzaki⁹, Navdeep
Sandhu⁵, Pradip Kumar Oli⁶, Hongquan Li⁷, Manu Prakash⁸, Ali Amid³, Rodrigo Onell³, Nicholas Au³,
Ha Sandhu", Pradip Kumar Oli", Hongquan Li', Manu Prakash", Ali Amid"
Hayley Merkeley³, Videsh Kapoor³, Rajan Pande^{6,9}, Boris Stoeber^{1,10*}
¹Department of Mechanical Engineering, The University of British Columbia, 2 , Rodrigo Onell^s, Nicholas Au^s
250 Applied Science Lane, Vancouve

,
er Hayley Merkeley", Videsh Kapoor", Rajan Pande"^{, 2}, Boris Stoeber^{4,46}
¹Department of Mechanical Engineering, The University of British Columbia, 2054-6
British Columbia, V6T 1Z4, Canada.
²Department of Mathematics a

²Department of Mathematics and Computer Science, Eindhoven University of Technology, Groene Loper 3, 5612 AE, Eindhoven,

British Columbia, V6T 124, Canada.
Department of Mathematics and Computer Science, Eindhoven University of Technology, Groene Loper 3, 5612 AE, Eindh
The Netherlands.
Division of Hematology & Oncology, BC Children's Hospit Primar Pramara, 1911-12, Panada.
²Department of Mathematics and C
The Netherlands.
³Faculty of Medicine, The University
Canada.
⁴Division of Hematology & Oncology
⁵Adult Red Cell Disorders Program c
1Y6, Canada. Department of Medicine, The University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, British Columbia, V6T 123, Canada.
Division of Hematology & Oncology, BC Children's Hospital, 4480 Oak Street, Vancouver ³Faculty of Medici
Canada.
⁴Division of Hema
⁵Adult Red Cell Di:
1Y6, Canada.
⁵Division of Hema ³Faculty of Medicine, The University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, British Columbia, V6T 123,

 4 Division of Hematology & Oncology, BC Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, V6H 3V4, Canada.

Fanada.
Division of Hematology & Oncology, BC Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, V6H 3V4, Canada.
Adult Red Cell Disorders Program of BC and Yukon, St. Paul's Hospital, 1081 Burrard Street, Andram
Adult Repart
Division
Spivision
Computer
Repart
Pepart
Repart Division of Hematology & Oncology BC Division of BC and Yukon, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, V6Z
2.
Y6, Canada.
Division of Hematology, Providence Health Care, 440-1144 Burrard Stre ⁵Adult Red Cell Disorders Program of BC and Yukon, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, V6Z Adult Red Cell Disorders Providence Health Care, 440-1144 Burrard Street, Vancouver, British Columbia, V6Z 2A5, Canada.
Adult Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj, Bheri Zone, Province no-5, Nepal.
Depart

 5 Division of Hematology, Providence Health Care, 440-1144 Burrard Street, Vancouver, British Columbia, V6Z 2A5, Canada.

⁶Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj, Bheri Zone, Province no-5, Nepal.

⁷Department of Electrical Engineering, Stanford University, 350 Jane Stanford Way, Stanford, California, USA.

 8 Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California, USA.

⁹Department of Internal Medicine, Bheri Hospital, Nepalgunj, Bheri Zone, Province no-5, Nepal.

⁵Division of H
⁶Mount Sagar
⁷Department
⁸Department
⁹Department
¹⁰Department Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj, Bheri Zone, Province no-5, Nepal.
Department of Electrical Engineering, Stanford University, 350 Jane Stanford Way, Stanford, California, USA.
Department of Bio Department of Electrical Engineering, Stanford University, 350 Jane Stanford Way, Stanford, Califo
Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California, USA.
Department of Internal Medici Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California, USA.
Department of Internal Medicine, Bheri Hospital, Nepalgunj, Bheri Zone, Province no-5, Nepal.
⁰Department of Electrical and Co Department of Internal Medicine, Bheri Hospital, Nepalgunj, Bheri Zone, Province no-5, Nepal.

⁹Department of Electrical and Computer Engineering, The University of British Columbia, 2332

0.

2. Columbia, V6T 1Z4, Canad OREGIST OF THE UNIVERSITY OF THE UNIVERSITY OF British Columbia, 2332 I
Diumbia, V6T 1Z4, Canada.
Corresponding authors (email: pranav.shrestha@alumni.ubc.ca; boris.stoeber@ubc.ca) 10Department of Electrical and Computer Engineering, The University of British Columbia, 2332 Main Mall, Vancouver, British Columbia, VGT 124, Canada.
Columbia, VGT 124, Canada.
* Corresponding authors (email: pranav.shres

Example, V6T 1Z4, Canada.
* Corresponding authors (en

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

<p>\nAbstract
\n2 Sickle cell disease (SCD) and β-thalassemia are the most common monogenic diseases,
\ndisproportionately affecting low- and middle-income countries, where low-cost and accurate diagnoses
\ntools are needed to reduce the global disease burden. Although the sickling test is commonly used to\n</p> 2 disproportionately affecting low- and middle-income countries, where low-cost and accurate diagnostic
2 tools are needed to reduce the global disease burden. Although the sickling test is commonly used to
2 screen for t 3 tools are needed to reduce the global disease burden. Although the sickling test is commonly used to
3 screen for the sickle mutation, it cannot distinguish between the asymptomatic sickle cell trait (SCT) and
3 SCD, or 4 to the measure the global distinguish between the asymptomatic sickle cell trait (SCT) a
4 SCD, or identify β-thalassemia. Here, we enhanced the inexpensive sickling test using automated
4 microscopy and morphology-base 5 SCD, or identify β-thalassemia. Here, we enhanced the inexpensive sickling test using automated
3 microscopy and morphology-based machine learning classification to detect SCD, trait conditions (SCT
3 and β-thalassemia 6
6 This is and β-thalassemia trait) and normal individuals with an overall area under receiver operating curv
6 Sensitivity and specificity of 0.940 (95% confidence intervals: 0.938-0.942), 84.6% (84.2%-84.9%),
6 Sensiti 2 and β-thalassemia trait) and normal individuals with an overall area under receiver operating curve,
19 sensitivity and specificity of 0.940 (95% confidence intervals: 0.938-0.942), 84.6% (84.2%-84.9%), and
192.3% (92.1 8 and β-thalassemia trait) and normal individuals multiple individuals multiple specifies specific of the sensitivity and specificity to detect severe disease (S was over 97% and 98%, respectively, thus establishing a low-92.3% (92.1%-92.4%), respectively. Notably, the sensitivity and specificity to detect severe disease (SC
was over 97% and 98%, respectively, thus establishing a low-cost automated screening option for
disease detection in 11 was over 97% and 98%, respectively, thus establishing a low-cost automated screening option for
12 disease detection in low-resource settings. Furthermore, leveraging high-throughput microscopy, we
13 generated an open-12 disease detection in low-resource settings. Furthermore, leveraging high-throughput microscopy,
13 generated an open-access dataset comprising over 300,000 images with 1.5 trillion segmented cel
14 from 138 individuals disease detection in low-resource settings. Furthermore, leveraging high-throughput microscopy, were generated an open-access dataset comprising over 300,000 images with 1.5 trillion segmented cells
14 from 138 individual 14 from 138 individuals in Canada and Nepal including individuals with sickle and/or β-thalassemia
15 mutations, to accelerate further research.
16 **Introduction** 15 individuals individuals individuals in Canada and Nepal including individuals with sickle and $\frac{1}{2}$ in the following individuals with sickle and $\frac{1}{2}$ in the following individuals with sickle and $\frac{1}{2}$ in th

17 Sickle cell disease (SCD) is linked with an estimated 300,000-400,000 births every year and a mortality
18 mate exceeding 50% in certain areas of low-income countries^{1,2}. SCD is caused by a mutation in the gen 16 **Introduction**
17 Sickle cell disease (SC
18 rate exceeding 50% in
19 encoding hemoglobir 18 rate exceeding 50% in certain areas of low-income countries^{1,2}. SCD is caused by a mutation in the gene
19 encoding hemoglobin β -globin subunit (HBB) resulting in a variant form of hemoglobin (HbS or sickle
20 hem encoding hemoglobin β-globin subunit (HBB) resulting in a variant form of hemoglobin (HbS or sickle
20 hemoglobin). HbS causes red blood cells (RBCs) to distort into rigid "sickled" cells that can lead to
21 blockage of 19 bet of the control of the control of the control of the moglobin). HbS causes red blood cells (RBCs) to distort into rigid "sickled" cells that can lead to
21 blockage of blood vessels (vaso-occlusion)^{1,3,4}, hemolysi 21 blockage of blood vessels (vaso-occlusion)^{1,3,4}, hemolysis, inflammation and progressive organ
22 damage^{4,5}. β-thalassemia is another inherited disease most commonly caused by point mutations
23 HBB, resulting in e blockage of blood vessels (vaso-occlusion)***, hemolysis, inflammation and progressive organ
22 damage^{4,5}. β-thalassemia is another inherited disease most commonly caused by point mutation
23 HBB, resulting in either a damaget HBB, resulting in either a reduced ($β⁺$) or absent ($β⁰$) synthesis of $β$ chains of hemoglobin⁶. SCD is an

24 umbrella term for a combination of inherited diseases, including sickle cell anemia (h HBB, resulting in either a reduced (β⁺) or absent (β0) synthesis of β chains of hemoglobin⁶ 23 . SCD is an 25 and compound heterozygous sickle cell disease (HbS/ β -thalassemia, HbS/C, *etc.*). Inheritance of a
26 mutated gene from only one parent results in clinically asymptomatic, but carrier forms, such as sickle
27 cell t 25 and compound neterozygous sickle cen disease (HbS/β-thalassemia, HbS/c, etc.). Inheritance or a
26 mutated gene from only one parent results in clinically asymptomatic, but carrier forms, such as si
27 cell trait (SCT; 27 cell trait (SCT; HbAS) and β -thalassemia trait (HbA/ β -thalassemia)⁷, which are usually more prevalent
28 than disease forms⁵. Screening for trait conditions (SCT and β -thalassemia trait) is also essential 27 cell trait (SCT; HbAS) and β-thalassemia trait (HbA/β-thalassemia)⁷, which are usually more prevale
28 than disease forms⁵. Screening for trait conditions (SCT and β-thalassemia trait) is also essential to than disease forms³. Screening for trait conditions (SCT and β-thalassemia trait) is also essential to that that
that is also essential to the sense of the sense is also essential to the sense of the sense is also essen

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

29 prevent the variant genes from being unknowingly transferred to children, potentially even as severe
30 disease forms.
31 Globally, HbS has the highest prevalence in sub-Saharan Africa, while HbS and β-thalassemia are 31 Globally, HbS h
32 prevalent in the
33 hemoglobin bio 32 prevalent in the Middle East, Mediterranean countries and South Asia^{4–6}. Although the genetics and
33 hemoglobin biophysics of SCD, the first "molecular disease"⁸, have been extensively studied⁴, and
34 promising prevalent in the Middle East, Mediterranean countries and South Asia⁺ °. Although the genetics and
33 hemoglobin biophysics of SCD, the first "molecular disease"⁸, have been extensively studied⁴, and
34 promising ne hemoglobin biophysics of SCD, the first "molecular disease"⁹, have been extensively studied", and

34 promising new techniques such as CRISPR-Cas9 gene editing for SCD and β-thalassemia have been

35 clinically tested 35 clinically tested⁹, there is still an unmet need to overcome the diagnostic barrier in low-resource
36 settings, where the burden of the disease is disproportionately high^{10,11}. Access to screening, caregeducation clinically tested², there is still an unmet need to overcome the diagnostic barrier in low-resource
36 settings, where the burden of the disease is disproportionately high^{10,11}. Access to screening, care
37 education a settings, where the burden of the disease is disproportionately high^{10,11}. Access to screening, caregiver
education and treatment options greatly improve quality of life and life expectancy of people with SCD,
and reduc 38 and reduce childhood mortality by up to 90%^{1,12}. However, the burden of the disease is highest in
39 resource-constrained regions of low- and middle-income countries, with limited access to such
30 screening and treat and reduce childhood mortality by up to 90%^{+,12}. However, the burden of the disease is highest in
139 resource-constrained regions of low- and middle-income countries, with limited access to such
10 screening and treatme 39 screening and treatment options. To enable timely and equitable diagnosis, low-cost and point-
41 detection techniques are required in such low-resource settings to supplement or replace expe
22 clinical laboratory tech detection techniques are required in such low-resource settings to supplement or replace expensive
dinical laboratory techniques¹¹.
43 Gold standard tests for detecting most hemoglobinopathies like SCD and β -thalasse

clinical laboratory techniques**.
43 . Gold standard tests for detecting
44 . hemoglobin (Hb) electrophoresis
45 . separating different variants of h

44 hemoglobin (Hb) electrophoresis and high performance liquid chromatography (HPLC), which rely on A4 hemoglobin (Hb) electrophoresis and high performance liquid chromatography (HPLC), which re
45 separating different variants of hemoglobin based on charge¹³. Hb HPLC is run on expensive equ
46 in clinical laboratorie

14 and them gentlectrophoresis and high performance liquid since the superior (HPLC) separating different variants of hemoglobin based on charge¹³. Hb HPLC is run on expensive equipment in clinical laboratories by highly

qually transformation resource-constrained settings. Conventional low-cost alternatives, such as the sickling

48 test and Hb solubility test, detect the presence of HbS, but do not differentiate between SCT and SCD. I

4

separating different variants of hemoglobin based on charge¹³. Hb HPLC is run on expensive equipment
in clinical laboratories by highly trained personnel, thus is not suitable for disease detection in
rural/remote or res

48 test and Hb solubility test, detect the presence of HbS, but do not differentiate between SCT and SCD. I
49 the sickling test, blood is sealed between a microscope slide and a coverslip with a reagent that causes
50 deo

49 the sickling test, blood is sealed between a microscope slide and a coverslip with a reagent that causes
50 deoxygenation (hypoxia), which induces sickling of RBCs for individuals with SCT and SCD^{7,13}. The
51 solubil deoxygenation (hypoxia), which induces sickling of RBCs for individuals with SCT and SCD^{7,13}. The
51 solubility test relies on the principle that HbS is insoluble in a high molarity phosphate buffer when
52 deoxygenated olubility test relies on the principle that HbS is insoluble in a high molarity phosphate buffer when
152 . deoxygenated, resulting in a turbid solution (positive test for SCT and SCD)⁷.
153 . Recently, novel approaches

deoxygenated, resulting in a turbid solution (positive test for SCT and SCD)'.
53 . Recently, novel approaches for detecting SCD have been developed or comm
54 . commercially available lateral-flow assays, HemoTypeSC and S

54 commercially available lateral-flow assays, HemoTypeSC and Sickle SCAN, detect HbS and variant Example a commercially available lateral-flow assays, HemoTypeSC and Sickle SCAN, detect HbS and variances for
55 Remoglobin C (HbC), with reported sensitivity and specificity of over 92%^{14–20}. A low-cost papel electroph

14 Commercially aranged areas are also general-flow and specificity of over 92%^{14–20}. A low-cost paper-bar electrophoresis platform, the Gazelle Hb variant test, has also been commercialized to detect HbS and β-thalasse

hemoglobin C (HbC), with reported sensitivity and specificity of over 92%^{44–20}. A low-cost paper-based
E6 electrophoresis platform, the Gazelle Hb variant test, has also been commercialized to detect HbS, Hb
and β-thala

and β -thalassemia²¹. The lateral flow assays and the Gazelle cost between \$2 to \$5 per test (with an
58 additional one-time cost of \$1200 for the Gazelle portable reader), and are around an order of and β-thalassemia²¹. The lateral flow assays and the Gazelle cost between \$2 to \$5 per test (with 58
58 additional one-time cost of \$1200 for the Gazelle portable reader), and are around an order of

 58.8 ± 0.0 for time cost of 51.20 ± 0.0 for the Gazelle portable reader), and are around an order of 31.2 ± 0.0

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

59 magnitude costlier per test than the sickling test. Despite the importance of screening for β-thalassemia
50 (including β-thalassemia trait) in areas with high prevalence of both HbS and β-thalassemia, none of the
51 c

61 (including β-thalassemia trait) in areas with high prevalence of both Habsemia.
62 The morphological differences between sickled and round RBCs can be observed through microscopy, which makes digital microscopy, augmen 62 Commercialization of the commence (except Cazelle) detect point and the morphological differences between sickled and round RBCs can be obsemble).
63 Which makes digital microscopy, augmented with machine learning, a p 63 which makes digital microscopy, augmented with machine learning, a potentially powerful tool for
64 disease identification. Most machine learning approaches thus far focus on identifying sickle cells in
65 microscopy i 64 disease identification. Most machine learning approaches thus far focus on identifying sickle cells in
65 microscopy images of peripheral blood smears, using techniques such as semantic segmentation²²,
66 classificati microscopy images of peripheral blood smears, using techniques such as semantic segmentation²², c
classification on segmented cells from datasets using lightweight models (*e.g.* support vector machin
multi-class classif microscopy images of peripheral blood smears, using techniques such as semantic segmentation²², or
classification on segmented cells from datasets using lightweight models (*e.g.* support vector machine
67 multi-class cl multi-class classifiers)²³ or deep convolutional neural networks²⁴. Although high accuracy of 98-99% has
68 been demonstrated using such techniques, sickle cells are usually only observed in peripheral blood
59 smears been demonstrated using such techniques, sickle cells are usually only observed in peripheral blood

smears for SCD samples and not for SCT samples, thus preventing the use of such techniques to scre

70 to trait condition Source and Source using such techniques, since the meaning the use of such techniques to scree
for trait conditions. To overcome this limitation, another approach analysed microscopy images of the
sickling test, instead of For trait conditions. To overcome this limitation, another approach analysed microscopy images of the
SCD sickling test, instead of peripheral blood smears. SCD and SCT were distinguished based on
T2 morphological differen 11 sickling test, instead of peripheral blood smears. SCD and SCT were distinguished based on
12 morphological differences between cells using high and low concentrations of a sickling reagent, but the
13 technique require morphological differences between cells using high and low concentrations of a sickling rearrive distinguished on the peripheral blood smears. The technique required using two reagent concentrations and a custom microfluid 12 technique required using two reagent concentrations and a custom microfluidic chamber²⁵.
14 Furthermore, most of these machine-learning based techniques have only been validated on thousands
15 of cells, thus highligh technique required using two reagent concentrations and a custom microfluidic chamber²⁵.
T4 . Furthermore, most of these machine-learning based techniques have only been validated or
T5 . of cells, thus highlighting a ke of cells, thus highlighting a key challenge with these techniques - *i.e.* having limited annotated data for
The training models. Although transfer learning, data augmentation and lightweight model architectures can
The us 25 of cells, thus inginighting a key challenge with these techniques - i.e. having limited annotated data for
26 training models. Although transfer learning, data augmentation and lightweight model architectures ca
27 be u Training models. Although transfer learning, data augmentation and lightweight model architectures can
Transferences with small datasets²³, high-throughput microscopy can potentially generate large image
datasets and agg 77 be used to work with small datasets²³, high-throughput microscopy can potentially generate large image
178 datasets and aggregation of morphological data can be utilized to avoid annotating at the single cell
179 leve

18 datasets and aggregation of morphological and stand cannotating at the single celling to avoid and all and
19 devel (when patient-level ground truth is available).
18 develops and morphological data can be utilized to 79 1999 Here, we introduce an augmented version of the ine
79 Mere, we introduce an augmented version of the ine
79 States of the sickling test (inability to disting
82 Shortcomings of the sickling test (inability to disti 81 microscopy and machine learning to detect SCD, SCT and β-thalassemia (Fig. 1a). We address the ma
82 shortcomings of the sickling test (inability to distinguish between SCT and SCD, inability to detect β-
83 thalassemi 82 shortcomings of the sickling test (inability to distinguish between SCT and SCD, inability to detect β-
83 thalassemia, and requirement of trained personnel to find sickle cells under a microscope), while
84 retaining 82.82 shortcomings of the sickling test (inability to distinguish between $S\subset\mathbb{R}^2$ 83 thalassemia, and requirement of trained personnel to find sickle cells under a microscope), while 85 sickling reagent and easily available consumables, no requirement for staining or fixing cells, and
86 reliance on the morphology of RBCs for detection). Using high-throughput low-cost microscopy, we
87 generated a larg Framing reagent and easily aramining remainingly reagain requirement for reading realing reading
85 september on the morphology of RBCs for detection). Using high-throughput low-cost microscopy, v
88 collected at clinical 86 reliance on the morphology of RBCs for detection). Using high-throughput low-cost microscopy, we
87 generated a large open-access dataset of microscopic images of blood cells from de-identified samples
88 collected at c collected at clinical sites in Canada and Nepal, suitable for statistical analysis and machine learning. Our

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

-
-
- and differences in cell shape and size between normal and β -thalassemia trait. The study aims to enable
- 89 classification approach is based on morphological differences between groups, relying on differences in cell shapes between normal and sickled cells, differences in the level of sickling between SCD and SCT, and diffe 92 inexpensive and automated screening of SCD and trait conditions (SCT, β-thalassemia trait), and improve
93 access to screening in low-resource settings.
94 **ReSUItS**
- experiment active and automated screening of SCD and trait conditions (SCD and trait conditions of SCD and traitions (SCT, $\frac{1}{2}$

94 Results
95 High-throughput automated micr Results
95 **High-throughput automated microscopy of sickling test and creation of
96 open-access image dataset**
97 A total of 138 participants were recruited in Nepal and Canada: 30 without β-globin disorders (HbAA), 23

**High-throughput automated microscopy of sickling test and creation of

open-access image dataset**

A total of 138 participants were recruited in Nepal and Canada: 30 without β-globin disorders (HbA,

with β-thalassemia t **open-access image dataset**
97 A total of 138 participants were recruited in Nepal and Canada: 30 without β-globin disorders (HbAA),
98 with β-thalassemia trait (HbA/β-thalassemia), 45 with SCT (HbAS), and 40 with SCD (11 100 test for high-throughput imaging and cell segmentation (more details in Methods). For each participant,
101 3-6 microscope slides (with 2 coverslips each) were prepared (Fig. 1a) and 225 images were captured $\frac{98.37}{1000}$, and $\frac{1}{300}$, 1999 that the sample preparation (more details in Methods). For each participal
1999 that for high-throughput imaging and cell segmentation (more details in Methods). For each participal
1999 13-6 microscope slides (with 2 101 3-6 microscope slides (with 2 coverslips each) were prepared (Fig. 1a) and 225 images were captured
102 per coverslip in around 4 minutes by the Octopi microscope^{26,27}, with automated slide scanning and
103 automated 102 per coverslip in around 4 minutes by the Octopi microscope^{26,27}, with automated slide scanning and
103 automated focusing (Fig. 1b). Two hours after sample preparation, RBCs from normal (HbAA; Fig. 1c)
104 and β-tha per coverslip in around 4 minutes by the Octopi microscope^{26,27}, with automated slide scanning and

automated focusing (Fig. 1b). Two hours after sample preparation, RBCs from normal (HbAA; Fig. 1c)

and β-thalassemia t 104 and β-thalassemia trait (HbA/β-thalassemia; Fig. 1d) participants appeared unchanged to the eye, wh
105 hypoxia-induced sickling was observed (Fig. 1e-g) for the majority of RBCs from SCD participants (HbS
106 thalass 105 hypoxia-induced sickling was observed (Fig. 1e-g) for the majority of RBCs from SCD participants (HbS/β-
106 thalassemia and HbSS), and for a fraction of RBCs from SCT participants (HbAS). The process of sickling,
107 and rate of deoxygenation²⁹²⁵. We followed consistent sample preparation and imaging protocols, such
109 that major differences between sickling of different samples resulted from differences in HbS
110 concentration, *i* 107 facilitated by the polymerization of HbS, depends on factors such as HbS concentration, temperature
108 and rate of deoxygenation^{28,29}. We followed consistent sample preparation and imaging protocols, such
109 that m and rate of deoxygenation^{28,29}. We followed consistent sample preparation and imaging protocols, such that major differences between sickling of different samples resulted from differences in HbS concentration, *i.e.* be 110 concentration, *i.e.* between SCT and SCD. Imaging 1001 coverslips from 138 participants, arou
111 220,000 images were captured 2 hours after sample preparation and around 1.2 trillion cells v
112 segmented using Cellp 110 concentration, *i.e.* between SCT and SCD. Imaging 1001 coversitys from 158 participants, around
111 220,000 images were captured 2 hours after sample preparation and around 1.2 trillion cells wer
113 classification. A 112 segmented using Cellpose 2.0³⁰ for statistical analysis and morphology-based machine learning
113 classification. All the de-identified microscopic images (raw and processed), cell segmentation data
114 calculated mo segmented using Cellpose 2.0³⁶ for statistical analysis and morphology-based machine learning
113 for classification. All the de-identified microscopic images (raw and processed), cell segmentation d
114 for calculated m 114 calculated morphological parameters for images captured at 2 hours and other parameter settings (*e.g.*
115 other time instances, other temperature configurations, time-series data) are publicly available in an
116 ope 114 calculated morphological parameters for images captured at 2 hours and other parameter settings (e.g.
115 other time instances, other temperature configurations, time-series data) are publicly available in an
116 open 116 open-access database³¹. 116 . open-access database³¹.
116 . .
.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Sickling under hypoxia
118 The reagent in the sickling test (s
119 environment of reduced oxygen
120 SCD). The resolution of imaging (119 environment of reduced oxygen or hypoxia, which induces sickling in RBCs with HbS (*i.e.* for SCT and
120 SCD). The resolution of imaging (pixel size of 1.85µm for monochromatic camera) using 20× objective
121 microsco 119 Environment of reduced oxygen or hypoxia, which induces sickling in RBCs with HBS (i.e. for SCT and
120 SCD). The resolution of imaging (pixel size of 1.85µm for monochromatic camera) using 20x objective
122 and 2). Si 121 microscopy was sufficient to observe sickling at the cellular level (Fig. 2a and Supplementary Videos 1
122 and 2). Sickling of RBCs produced detectable changes in some morphological parameters over time,
123 even at t and 2). Sickling of RBCs produced detectable changes in some morphological parameters over time,
123 even at the level of a single image, containing aggregated data from around 3000 cells (Fig. 2b-g and
124 Supplementary V 123 even at the level of a single image, containing aggregated data from around 3000 cells (Fig. 2b-g and
124 Supplementary Video 3). As an example for a participant with SCD, within a 50 minute time period, t
125 distribu 124 Supplementary Video 3). As an example for a participant with SCD, within a 50 minute time period, the distribution of area remained nearly constant (Fig. 2b), the perimeter distribution changed slightly (Fig. 2b), the 125 distribution of area remained nearly constant (Fig. 2b), the perimeter distribution changed slightly (Fig.
126 2c), and the distributions of major axis, minor axis, roundness, and eccentricity changed considerably
127 126 2c), and the distributions of major axis, minor axis, roundness, and eccentricity changed considerably
127 (Fig. 2d-g). The time evolution of the morphological parameters reflected the dynamics of RBC sickling,
128 e.g 127 (Fig. 2d-g). The time evolution of the morphological parameters reflected the dynamics of RBC sickling
128 e.g. the roundness peak (Fig. 2f) shifted from closer to 1 (round) to around 0.5 (elongated or sickled),
129 an (Fig. 2d-g). The time evolution of the morphological parameters reflected the dynamics of RBC sickling

28 e.g. the roundness peak (Fig. 2f) shifted from closer to 1 (round) to around 0.5 (elongated or sickled),

30 and th and the eccentricity peak (Fig. 2g) shifted from around 0.4 (less elongated) to around 0.9 (more
130 elongated or sickled), indicating that greater proportions of cells sickled over time.
131 **Morphological characterizatio** elongated or sickled), indicating that greater proportions of cells sickled over time.
131 **Morphological characterization at multiple scales**
132 Blood cells in microscopic images were segmented by fine-tuning a neural ne

131 **Morphological characterization at multiple scales**
132 Blood cells in microscopic images were segmented by fine-tuning a neural network
133 in Cellpose 2.0 using a human-in-the-loop approach³⁰. Based on the outlines **Morphological characterization at multiple scales**
132 Blood cells in microscopic images were segmented by fine-tuning a not
133 in Cellpose 2.0 using a human-in-the-loop approach³⁰. Based on the c
134 different paramet 132 Blood cells in microscopic images were segmented by fine-tuning a neural network-based model (Cyto)

133 in Cellpose 2.0 using a human-in-the-loop approach³⁰. Based on the outlines of the segmented cells, 40

134 di in Cellpose 2.0 using a human-in-the-loop approach³⁰. Based on the outlines of the segmented cells, 40
134 different parameters describing the size (*e.g.* area, perimeter), shape (*e.g.* roundness, eccentricity), and
13 134 different parameters describing the size (e.g. area, perimeter), shape (e.g. roundness, eccentricity), and
135 intensity (e.g. mean intensity) of the cells were calculated (complete list in Supplementary information).
 Intensity (e.g. mean intensity) of the cells were calculated (complete list in Supplementary information).
136 Different types of cells, including different variations of sickled cells (*e.g.* crescent, holly leaf, granula 137 bifferent types of cells, including different variations of sickled cells (e.g. crescent, holly leaf, granular),
137 bifferent values for morphological parameters (Fig. 2h). The morphological parameters
138 determined 138 determined at the cellular level were aggregated at different levels or scales – group level (colored
139 in Fig. 3), donor level (Fig. 3a), slide level, coverslip level (Fig. 3b), and image level (Fig. 3c). For inst
1 determined at the cellular level were aggregated at different levels or scales – group level (colored lines

in Fig. 3), donor level (Fig. 3a), slide level, coverslip level (Fig. 3b), and image level (Fig. 3c). For instanc the frequency distribution of eccentricity, which describes how elongated a shape is, was calculated for

141 all the cells per donor or participant (aggregating data for nearly 6-10 million cells per participant; Fig.

1 all the cells per donor or participant (aggregating data for nearly 6-10 million cells per participant; Fig.
142 3a). The distribution of eccentricity for normal ("AA" or HbAA) and β-thalassemia trait ("ABeta" or HbA
143 142 all the distribution of eccentricity for normal ("AA" or HbAA) and β-thalassemia trait ("ABeta" or HbA
143 β-thalassemia) were similar for image, coverslip and donor levels, with peaks close to 0.4 (less
144 elongated 142 3 B-thalassemia) were similar for image, coverslip and donor levels, with peaks close to 0.4 (less
144 elongated). The distribution of eccentricity of SCT ("AS" or HbAS) had two peaks at the group level
145 (colored l elongated). The distribution of eccentricity of SCT ("AS" or HbAS) had two peaks at the group louds
145 (colored lines in Fig. 3), indicating that a portion of the cells were sickled (high eccentricity) wh
146 rest were no 145 (colored lines in Fig. 3), indicating that a portion of the cells were sickled (high eccentricity) while the
146 Fest were not (low eccentricity). As indicated by the variability of frequency distribution profiles, not rest were not (low eccentricity). As indicated by the variability of frequency distribution profiles, not all 146 rest were not (low eccentricity). As indicated by the variability of frequency distribution profiles, not
146 rest were not all the variability of frequency distribution profiles, not all the variability of frequency
1

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

images in the SCT group contained sickled cells. In contrast, the SCD group (*i.e.* HbSS and HbS/β-
148 thalassemia) had prominent peaks at high values of eccentricity at all levels of analysis, indicating that
149 the im

149 the images contained predominantly sickled or elongated cells. Overall, the curves for SCD were
150 markedly different from the rest, while curves for AA and ABeta, and for AS and the rest overlapped.
151 **Statistical**

The imarkedly different from the rest, while curves for AA and ABeta, and for AS and the rest overlapp
151 **Statistical differences between morphological parameters of different**
152 **groups** 151 Statistical differences between morphological parameters of different
152 groups
153 To explore whether morphological differences existed between different groups, and to evaluate the

**Statistical differences between morphological parameters of different
152 groups**
153 To explore whether morphological differences existed between different groups, and to evaluate
154 feasibility of morpholo 152 **groups**
153 To explore
154 feasibility
155 distribution 154 For explore when the protogram and control interest control and control groups, and to evaluate the
154 feasibility of morphology-based classification, we calculated statistical differences between frequency
155 distri distributions of different groups for all 40 morphological parameters. This statistical analysis used data
156 for morphological parameters aggregated at the coverslip-level, with a total of 1001 coverslips from 13
157 par 156 for morphological parameters aggregated at the coverslip-level, with a total of 1001 coverslips from 13
157 participants for 4 clinically relevant groups – AA (HbAA), ABeta (HbA/β-thalassemia), AS (HbAS), and SC
158 (participants for 4 clinically relevant groups – AA (HbAA), ABeta (HbA/ß-thalassemia), AS (HbAS), and SCD
158 (HbS/ß-thalassemia and HbSS). For each morphological parameter, there were parameter ranges (or
159 bins in frequ 158 (HbS/β-thalassemia and HbSS). For each morphological parameter, there were parameter ranges (or
159 bins in frequency distribution curves or features for classification) without significant differences (p-
160 value > 158 (HbS/β-thalassemia and HbSS). For each morphological parameter, there were parameter ranges (or
159 bins in frequency distribution curves or features for classification) without significant differences (p-
160 value > many bins or features that resulted in significant differences (p-value < 0.05) between morphologies of
162 different (or all) groups, thus being important features for morphology-based classification. For
163 example, the 162 different (or all) groups, thus being important features for morphology-based classification. For
163 example, there were significantly different occurrences of cells with major axis between 10.5 µm and 1.
164 µm for 5 example, there were significantly different occurrences of cells with major axis between 10.5 µr
164 µm for 5 out of 6 combinations (grey box in Fig. 4a; and 4c-d), and with roundness between 0.89
165 0.92 for all 6 combin 164 example, there were significantly anti-time content of content in the major and content of the major para
164 example, there is the combinations (Fig 4e, 4g-h).
166 The statistical analysis results (Fig. 4) relate to o

165 164 0.92 for all 6 combinations (Fig. 4g-h).
166 1 The statistical analysis results (Fig. 4) relate to observed and expected physical or morphological
167 1 Characteristics of cells. Firstly, the differences between SC 166 The statistical analysis results (Fig. 4) relations (The statistical analysis results (Fig. 4) relations (indicated by lower power pow 267 Characteristics of cells. Firstly, the differences between SCD and the other classes were larger that
168 other combinations (indicated by lower p-values for C3, C5 and C6 than for other combinations in
169 4a,d,e,h), 168 other combinations (indicated by lower p-values for C3, C5 and C6 than for other combinations in Fig
169 4a,d,e,h), mainly because the cells from SCD samples were predominantly sickled (indicated by shifted
170 peaks i 169 *Aa,d,e,h), mainly because the cells from SCD samples were predominantly sickled (indicated by shifted peaks in frequency distribution in Fig. 4b,e), unlike cells from the other groups. However, since AA and AS (to som* 170 beaks in frequency distribution in Fig. 4b,e), unlike cells from the other groups. However, since AA and
171 ABeta, and AS (to some extent) had round RBCs, there were many bins without significant
172 morphological dif 171 ABeta, and AS (to some extent) had round RBCs, there were many bins without significant
172 morphological differences for combinations C1, C2, C4 (Fig. 4a,e). Regardless, even for these 3
173 combinations, there existe morphological differences for combinations C1, C2, C4 (Fig. 4a,e). Regardless, even for thes
173 combinations, there existed bins with significant morphological differences, likely due to th
174 some sickled cells in AS, a 173 combinations, there existed bins with significant morphological differences, likely due to the pr
174 some sickled cells in AS, and the variation in shape (poikilocytosis) and size (anisocytosis) of RB
175 expected in 174 some sickled cells in AS, and the variation in shape (poikilocytosis) and size (anisocytosis) of RBCs
175 expected in ABeta³². 175 expected in ABeta³². And the variation in shape (point $\frac{1}{2}$ and size $\frac{1}{2}$ and $\frac{1}{2}$ and 175 aexpected in ABeta³².
175 .
Textes in ABeta³² .

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

To compare the 40 different morphological parameters with respect to their relevance for sample

177 classification, the top bins or features for each morphological parameter were evaluated (Fig. 4i,j).

178 Considering th 178 Considering the minimum p-values for each combination of each morphological parameter (Fig. 4j)
179 almost all the parameters (236/240) had features with significant differences (Fig. 4j). Generally, no
180 dimensional almost all the parameters (236/240) had features with significant differences (Fig. 4j). Generally, nor
180 dimensional morphological parameters (red lines in Fig. 4i-j), such as roundness, eccentricity, norma
181 area, *e* 183 were selected for classification. Overall, based on statistical analyses, there were morphological 181 area, *etc.*, produced more significant differences than other parameters, such as area, perimeter, *etc.*
182 Additionally, non-dimensional parameters are robust and independent of imaging modalities, and thus
183 wer 182 Additionally, non-dimensional parameters are robust and independent of imaging modalities, and thue
183 were selected for classification. Overall, based on statistical analyses, there were morphological
184 differences 183 were selected for classification. Overall, based on statistical analyses, there were morphological
184 differences between the 4 groups at multiple bins for all 6 combinations, suggesting that morphology-
185 based cla 184 differences between the 4 groups at multiple bins for all 6 combinations, suggesting that morphological analysis of the 4 groups at multiple bins for all 6 combinations, suggesting that morphological based classificati based classification, particularly using frequency distribution from non-dimensional parameters, is

186 feasible.
 Morphology-based machine learning classification

188 Coverslip-level frequency distribution of 19 non-d

Morphology-based machine learning classification
188 Coverslip-level frequency distribution of 19 non-dimensional morphological parameters were used for
189 machine-learning classification, using 80:20 participant-wise s 187 **Morph**
188 Coverslip
189 machine machine-learning classification, using 80:20 participant-wise splits of training and testing data, which
190 were iteratively randomized 1000 times to obtain 95% confidence intervals (CI) of performance metrics
191 Differe 189 machine-learning classification, and good processes the participant-wise splits of training and testing data, which
189 machines is training to training the splits of training and testing of the different cases,
192 co 191 Different groups were considered (details in Methods): 3Gp, 3GpSc, and 4Gp. For the different cases,
192 confusion matrices and receiver operating characteristic (ROC) curves of top classifiers are provided in
193 Fig. 191 Different groups were considered (details in Methods): 3Gp, 3GpSc, and 4Gp. For the different cases,
192 confusion matrices and receiver operating characteristic (ROC) curves of top classifiers are provided in
194 Fig. 192 confusion matrices and receiver operating characteristic (ROC) curves of top classifiers are provided in
193 Fig. 5. Performance metrics (class-wise and overall) for the top 5 classifiers in each case are provided in
1

194 Fig. 6. (more metrics in Tables S1-S3 of Supplementary information).
195 The area under the ROC curve (AUC or AUROC) relates to the probability that a classifier will rank a
196 Tandomly chosen positive case higher tha 194 Fig. 6 (more means in Tables 1940) of Supplementary, the small of SI-S
195 The area under the ROC curve (AUC or AUROC) relates to the probak
197 The area under positive case higher than a randomly chosen negat
197 The 196 The area under the ROC curve (ROC curve Corrected Curve Curve Curve Curve Curve Curve Curve Curve Curve Cu
197 Classifier, quadratic support vector machine (QSVM), was able to discriminate the three classes typi
198 Co randomly chosen positive case higher than a randomly chosen negative case³³. For *3Gp*, the top
197 classifier, quadratic support vector machine (QSVM), was able to discriminate the three classes typically
198 considered 198 considered during HbS screening (Fig. 5a,d, 6d; upright triangles in Fig. 6a-c). The overall or macro-
199 averaged AUC, sensitivity, and specificity were 0.962 (95% CI: 0.961-0.963), 0.890 (0.888-0.892), and
190 0.945 $198.5₁₉$ considered during HbS screening (Fig. 5a,d, 6d; upright triangles in Fig. 6a-c). The overall or macro-1990 averaged Musik Comparts Comparts Comparation of 0.945 (0.944-0.946), respectively. Traditionally, the sickling test cannot distinguish between SCT (AS)
1991 SCD, but in this case (3Gp), the top machine learning classi 201 SCD, but in this case (3Gp), the top machine learning classifier distinguished AA (and ABeta), AS and SCD
202 with class-wise AUC (one vs. all) of 0.961 (0.96-0.963), 0.928 (0.925-0.93) and 0.997 (0.997-0.997),
203 res 201 SCD, but in this case (3Gp), the top machine learning classifier distinguished AA (and ABeta), A3 and 3CD
202 with class-wise AUC (one vs. all) of 0.961 (0.96-0.963), 0.928 (0.925-0.93) and 0.997 (0.997-0.997),
204 For

ير الله من المسلمين المسلمين والمسلمين المسلمين والمسلمين المسلمين والمسلمين والمسلمين والمسلمين والمسلمين وال
204 For 3GpSc, the overall AUC, sensitivity and specificity for the top classifier (QSVM) were 0.940 (0.93
205 204 For *3GpSc*, the overall AU 205 0.942), 0.846 (0.842-0.849 204 For 3GpSc, the overall AUC, sensitivity and specificity for the top classifier (QSVM) were 0.940 (0.938-
205 0.942), 0.846 (0.842-0.849), and 0.923 (0.921-0.924), respectively (Fig. 5e, 6e, and inverted triangles in 205 0.942), 0.846 (0.842-0.849), and 0.923 (0.921-0.924), respectively (Fig. 5e, 6e, and inverted triangles in

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

detecting disease and trait conditions were higher than for AA, indicating that most of the individuals

- 206 Fig. 6a-c). The class-wise AUC for AA, trait (ABeta & AS) and SCD were 0.922 (0.919-0.925), 0.901 (0.898-
207 0.903), and 0.998 (0.998-0.998), respectively. For most of the top 5 classifiers (Fig. 6e), the sensitivity
-
- 209 vith trait or disease conditions would be identified during screening, and such individuals could be
210 followed up with confirmatory diagnostic tests.
211 For 4Gp, the top classifier, subspace discriminant (SSD), was ى
210 followed up with confirmatory diagnostic tests.
211 For 4Gp, the top classifier, subspace discriminant (SSD), was able to discriminate 4 groups (AA, ABe[.]
212 AS, SCD) with a macro-averaged AUC of 0.921 (0.919-0.92 211 For 4Gp, the top classifier, subspace discriminar
212 AS, SCD) with a macro-averaged AUC of 0.921 (C
213 specificity of 0.921 (0.92-0.922) (Fig. 5c,f, 6f; squ
- 211 For 4Gp, the top classifier, subspace discriminant (SSD), was able to discriminate 4 groups (AA, ABeta,
212 AS, SCD) with a macro-averaged AUC of 0.921 (0.919-0.923), sensitivity of 0.763 (0.76-0.767), and
214 penaltie
-
- 213 specificity of 0.921 (0.92-0.922) (Fig. 5c, f, 6f; squares in Fig. 6a-c). Different misclassification
214 penalties/costs can also be applied depending on the requirements of screening tools, *e.g.* higher
215 penaltie 214 penalties/costs can also be applied depending on the requirements of screening tools, *e.g.* h
215 penalties for misclassification of trait or disease conditions than normal conditions increased
216 sensitivity of dete
-

214 penalties/costs can also be applied depending on the requirements of screening tools, e.g. migher
215 penalties for misclassification of trait or disease conditions than normal conditions increased the
216 sensitivity

- 216 sensitivity of detecting ABeta and AS (Fig. 6g). Additionally, feature selection can reduce computa
217 resource requirement with minimal effect on classifier performance, e.g. selecting the top 77 fea
218 based on sta 217 resource requirement with minimal effect on classifier performance, *e.g.* selecting the top 77 features
218 based on statistical analysis (Fig. 6h) resulted in comparable classification performance to that using all
2 217 resource requirement with minimal effect on classifier performance, e.g. selecting the top 77 reatures
218 based on statistical analysis (Fig. 6h) resulted in comparable classification performance to that using all
220
-
-
- 219 based on statistical analysis (Fig. 11) resulted in comparable classification performance to that using an
220 based on statistical analysis (Fig. 6f).
221 divisions, indicating that most of the severe disease cases we
- 220 Features from 20 morphological parameters (Fig. 27).
220 Motably, the sensitivity for detecting SCD was high (> 97%
222 Consistent with results from statistical analysis (Fig. 4) and 221 divisions, indicating that most of the severe disease cases were detected by the classifiers. This was
222 consistent with results from statistical analysis (Fig. 4) and observations of morphological differences
223 mi divisions, indicating that most of the severe disease cases were detected by the classifiers. This was

consistent with results from statistical analysis (Fig. 4) and observations of morphological differences in

microscop
- 223 microscopic images (Fig. 1).
224 **Discussion**
225 **Consistent With results from statistical differences in the more for more in the mo**

225 The low-cost sickling test, which is traditionally unable to distinguish between SCT and SCD and unable
226 to detect β-thalassemia, was augmented to detect individuals with/without SCD and trait conditions **Discussion**
225 The low-cost sickling test, which is traditionally unable to distinguish between SCT and SCD and unable
226 to detect β-thalassemia, was augmented to detect individuals with/without SCD and trait conditio 226 to detect β-thalassemia, was augmented to detect individuals with/without SCD and trait conditions
227 (including β-thalassemia) with an overall sensitivity and specificity of 84.6% (95% CI: 84.2%-84.9%), and
228 92.3 227 (including β-thalassemia) with an overall sensitivity and specificity of 84.6% (95% CI: 84.2%-84.9%), a
228 92.3% (92.1%-92.4%), respectively (with sensitivity to detect only SCD of 97.3%). Such an augmentati
229 of t 228 92.3% (92.1%-92.4%), respectively (with sensitivity to detect only SCD of 97.3%). Such an augmentation
229 of the simple sickling test can enable accurate identification (>97% sensitivity) of people with severe
230 di 229 of the simple sickling test can enable accurate identification (>97% sensitivity) of people with severe
230 disease who require treatment and medical attention, while also screening for individuals with trait
231 condi disease who require treatment and medical attention, while also screening for individuals with trait
231 conditions including β -thalassemia (85% sensitivity) who can be informed of the risks of passing varia
232 genes t 231 conditions including β-thalassemia (85% sensitivity) who can be informed of the risks of passing variant
232 genes to children. Furthermore, the portable microscope can be implemented in different levels of
233 health 232 genes to children. Furthermore, the portable microscope can be implemented in different levels of healthcare facilities without requiring a sophisticated laboratory/clinical setting. Moreover, the same 233 healthcare facilities without requiring a sophisticated laboratory/clinical setting. Moreover, the sam
233 healthcare facilities without requiring a sophisticated laboratory/clinical setting. Moreover, the same

233 healthcare facilities without requiring a sophisticated laboratory/clinical setting. Moreover, the same

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

235 as malaria²⁶ and tuberculosis³⁴.
235 as malaria²⁶ and tuberculosis³⁴.
236 The use of high-throughput automated microscopy for morphology-based classification provides
237 benefits to diagnostics in low-resource as malaria²⁶ and tuberculosis³⁴.
236 . The use of high-throughput auto
237 . benefits to diagnostics in low-re
238 . generating large training data so 237 benefits to diagnostics in low-resource settings, allows expert review, and represents a powerful
238 generating large training data sets for the development of advanced classification algorithms. First
239 automation 238 benefits to diagnostics in the development of advanced classification algorithms. Firstly,
239 automation can be implemented for device operation, slide scanning, and disease detection, reducing
240 the need for highly 239 automation can be implemented for device operation, slide scanning, and disease detection, reducing
240 the need for highly skilled personnel in low-resource settings. Secondly, if needed, the microscopic
241 images of 240 the need for highly skilled personnel in low-resource settings. Secondly, if needed, the microscopic
241 images of blood cells can be examined by specialists (*e.g.* hematologists, hematopathologists, laborato
242 tech 241 the needed for highly share personnel in the needed is schema for higher theoretically in a material person
242 the chnicians) to validate test results, similar to analysing a conventional sickling test for sickled cel 241 images of blood cells can be examined by specialists (*e.g.* hematologists, hematopathologists, laborat
242 technicians) to validate test results, similar to analysing a conventional sickling test for sickled cells to screen for HbS or a peripheral blood smear for poikilocytosis or anisocytosis of RBCs to screen for β-
244 thalassemia. Furthermore, morphological characterization performed at coverslip-, donor-, or group
245 levels can 243 screen for HbS or a peripheral blood smear for point point point point point point point point point point
De BCs to screen for β-Cs to scre 2444 thalassemia. Furthermore, morphological characterization performed at coverslip-, donor-, or group-, or group-, or group-, α 246 analysis at a scale orders of magnitude greater than with individual inspection of images. Such
247 morphological and aggregated characterization of cells relates to physical and observable differer
248 between cells o 247 and the contract of magnitude greater than that manufacturing proton integration
248 between cells of different groups. Thus, these morphological parameters serve as meaningful i
249 machine-learning based classificati 247 morphological and aggregated characterization of cells relates to physical and observable differences
248 between cells of different groups. Thus, these morphological parameters serve as meaningful inputs to
249 machin machine-learning based classification and can enhance the interpretability of the classification process
250 and results, which is important for health-care related machine learning applications^{35,36}. Lastly, high-
251 t 250 and results, which is important for health-care related machine learning applications^{35,36}. Lastly, high-
251 throughput imaging enabled the creation of an open-access image dataset with hundreds of thousands
252 of and results, which is important for health-care related machine learning applications^{39,36}. Lastly, high-
251 throughput imaging enabled the creation of an open-access image dataset with hundreds of thousand
252 . The fi 252 of images and trillions of segmented cells with ground truth diagnosis from Hb HPLC, which can be used
253 in the future to further improve classification performance, as segmentation/classification algorithms
254 impr 253 in the future to further improve classification performance, as segmentation/classification algorithms
254 improve over time. Furthermore, the same dataset can be used for disease detection using other
255 approaches n 254 improve over time. Furthermore, the same dataset can be used for disease detection using other
255 approaches not considered here, such as semantic segmentation or object detection.
256 In comparison with other low-cos

254 improve over time. Furthermore, the same dataset can be used for disease detection using other
255 approaches not considered here, such as semantic segmentation or object detection.
256 In comparison with other low-co 256 and comparison with other low-cost tests, the overall sensitivity and specificity to detection.
257 approaches Here, Such as Semantic Serversity and Secificity to detection.
258 a. 8 99.3%), HemoTypeSC (74.4% & 94.4%) 257 HbS and β-thalassemia were (ClinicalTrials gov Identifier: NCT05506358): Gazelle Hb variant test (97.0%
258 & 99.3%), HemoTypeSC (74.4% & 94.4%), and Sickle SCAN (75.0% & 94.7%)^{37,38}. In terms of cost, the
259 othe 258 & 99.3%), HemoTypeSC (74.4% & 94.4%), and Sickle SCAN (75.0% & 94.7%)^{37,38}. In terms of cost, the
259 other point-of-care techniques are 2-10 times more expensive than the augmented sickling test for
260 running 10, & 99.3%), HemoTypeSC (74.4% & 94.4%), and Sickle SCAN (75.0% & 94.7%)^{37,38}. In terms of cost, the
259 . other point-of-care techniques are 2-10 times more expensive than the augmented sickling test for
260 . running 10, 260 running 10,000-100,000 tests (Fig. 7), where the costs for the augmented sickling test include a one
261 cost for the automated microscope (< \$3,000), and inexpensive readily-available consumables (<\$0.
262 test) such 261 cost for the automated microscope (< \$3,000), and inexpensive readily-available consumables (<\$0.5 per
262 test) such as microscope slides, coverslips, powdered reagent, and distilled water. Furthermore, only the 261 cost for the automated microscope (< \$3,000), and inexpensive readily-available consumables (<\$0.5 per test) such as microscope slides, coverslips, powdered reagent, and distilled water. Furthermore, only the 10 262 test) such as microscope slides, coverslips, powdered reagent, and distilled water. Furthermore, only the

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

264 Gazelle and the augmented similar can detect β-thalassemia.
264 Gazellens with high prevalence of both HbS and β-thalassemia.
265 There are some limitations associated with the diagnostic technique and with the data u 265 Ferral Collies with the diagnostic tectors with the diagnostic tectors with the diagnostic tectors of the analysis relied on microscopic images, the model of three-dimensional (3D) centiles with the dimensional (3D) ce There are some limitations associated with the diagnostic technique and with the data used in this
266 study. Since the analysis relied on microscopic images, the morphological characterization was based on
267 two-dimensi 269 strudting in round cells being detected as elliptocytic cells, a common limitation of blood cell imaging-
270 Shased diagnostic techniques. However, the occurrence of side-lying cells appeared to be negligible 270 based diagnostic techniques. However, the occurrence of side-lying cells appeared to be negligible
271 compared to flat-lying RBCs, and such cells appeared in both training and testing datasets. At the cl round, meaning in round cells being detected as elliptocytic cells, a common limitation of blood cell imagin
270 based diagnostic techniques. However, the occurrence of side-lying cells appeared to be negligible
271 compar 272 configurations for time (2 hours) and temperature (room temperature), only a fraction of RBCs from SCT
273 samples sickled. Although this served as a basis for differentiating between SCT and SCD, and resulted in 271 compared to flat-lying RBCs, and such cells appeared in both training and testing datasets. At the cl
272 configurations for time (2 hours) and temperature (room temperature), only a fraction of RBCs fror
273 samples s 272 configurations for time (2 hours) and temperature (room temperature), only a fraction of RBCs from SCT
273 samples sickled. Although this served as a basis for differentiating between SCT and SCD, and resulted in
274 h 273 samples sickled. Although this served as a basis for differentiating between SCT and SCD, and resulted in
274 high sensitivity to detect SCD, the incubation time or temperature can be increased to increase the
275 numb high sensitivity to detect SCD, the incubation time or temperature can be increased to increase the
275 number of sickled cells for SCT, likely increasing the sensitivity to detect SCT. Furthermore, some
276 nisclassifica 275 https://www.factory.com/sensitivity to detect SCT. Furthermore, some
276 misclassifications between normal and β-thalassemia trait could possibly arise due to other factors
277 as iron deficiency (not evaluated in thi 276 misclassifications between normal and β -thalassemia trait could possibly arise due to other facto as iron deficiency (not evaluated in this study), which can affect the RBC shape and size. Future st could include i 277 as iron deficiency (not evaluated in this study), which can affect the RBC shape and size. Future studies
278 could include information such as ferritin level to account for other such confounding factors (e.g. iron
27 278 could include information such as ferritin level to account for other such confounding factors (e.g. iron
279 deficiency) that affect cell morphology. The duration of storage for blood samples also affects RBC
280 shap 278 could include information such as ferrith level to account for other such comounting factors (e.g. non
279 deficiency) that affect cell morphology. The duration of storage for blood samples also affects RBC
281 could 280 shape, and storage artifacts (some RBCs becoming echinocytic) were observed in some cells, which
281 could limit the classification performance, especially between normal and β -thalassemia trait samp
282 Our study 281 could limit the classification performance, especially between normal and β -thalassemia trait sampl
282 Our study did not include β -thalassemia major patients because of their requirement for regular (*i.e*
283 282 Cur study did not include β-thalassemia major patients because of their requirement for regular (*i.e.*
283 around monthly) blood transfusions, which would affect the test results. Additionally, as HbC mutation
284 is 282 Our study did not include p-charassemia major patients because of their requirement for regular (i.e.
283 around monthly) blood transfusions, which would affect the test results. Additionally, as HbC mutatic
285 was n around monthly) blood transfusions, which would affect the test results. Additionally, as HbC mutation
284 is not encountered in Nepal, people with HbSC or HbAC were not included, and the algorithm therefore
285 was not tr

285 is not trained to distinguish these conditions.
285 is not trained to distinguish these conditions.
286 In summary, automated microscopy and morphology-based classification enhanced the performance of the sickling test 286 his summary, automated microscopy and morph
287 the sickling test, and appears suitable to serve a
288 cell disease and β-thalassemia in low-resource s 287 the sickling test, and appears suitable to serve as a low-cost automated screening tool to detect sickle
288 cell disease and β -thalassemia in low-resource settings, where the disease burden is often the highest. 287 the sickling test, and appears suitable to serve as a low-cost automated screening tool to detect sickle
288 cell disease and β-thalassemia in low-resource settings, where the disease burden is often the highest. 288 cell disease and β-thalassemia in low-resource settings, where the disease burden is often the highest.
- The highest.
- The highest.

11

Materials and Methods
290 **Study design and participants**
291 The study (ClinicalTrials.gov Identifier: NCT05506358) was conducted in two countries – Canada and
292 Nepal. Blood collection and tests completed in Canada b **Study design and participants**
291 The study (ClinicalTrials.gov Identifier: NCT05506358) was conducted in two countries – Canada and
292 Nepal. Blood collection and tests completed in Canada between September 2022 – Marc 294 (at Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj). A total of 138 participants were
295 recruited (ages 2-74 years; 59% female, 41% male). The diagnoses for all participants, except normal 292 Paul's Hospital and BC Children's Hospital, Vancouver), and in Nepal in November and December 2022
294 (at Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj). A total of 138 participants were
295 recruited (294 (at Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj). A total of 138 participants were
295 recruited (ages 2-74 years; 59% female, 41% male). The diagnoses for all participants, except normal
296 controls 295 recruited (ages 2-74 years; 59% female, 41% male). The diagnoses for all participants, except normal
296 controls or healthy volunteers without known β-globin disorders, had been previously established by
297 hemoglob 296 controls or healthy volunteers without known β-globin disorders, had been previously established by
297 hemoglobin high performance liquid chromatography (Hb HPLC). Confirmatory Hb HPLC was performed
298 on all parti 297 controls or healthy volunteers with the though generate the state of protocols of the theorem.
298 control on all participants and there were 30 normal (HbAA), 23 β-thalassemia trait (HbA/β-thalassemia), 45
299 sickle 298 on all participants and there were 30 normal (HbAA), 23 B-thalassemia trait (HbA/B- thalassemia), 45
299 sickle cell trait (HbAS), and 40 sickle cell disease (11 HbS/B-thalassemia and 29 HbSS) participants.
300 Partic 299 sickle cell trait (HbAS), and 40 sickle cell disease (11 HbS/β-thalassemia and 29 HbSS) participants.
200 Participants older than 1 year were eligible. Exclusion criteria were pregnancy or blood transfusion
201 within 299 Starticipants older than 1 year were eligible. Exclusion criteria were pregnancy or blood transfusion
201 within 3 months. Informed consent was provided by the participants or parents, according to proto
202 Shapproved 301 within 3 months. Informed consent was provided by the participants or parents, according to proto
302 approved by institutional/national research ethics boards. The study protocols and documents were
303 reviewed and a 302 approved by institutional/national research ethics boards. The study protocols and documents were
303 reviewed and approved for the Canada study by the University of British Columbia-Providence Health
304 Care Research 302 approved by institutional/national research ethics boards. The study protocols and documents were
303 reviewed and approved for the Canada study by the University of British Columbia-Providence Health
304 Care Research 304 Care Research Institute (UBC-PHC REB Number: H21-01929), and for the Nepal study by the University
305 British Columbia Clinical Research Ethics Board (UBC CREB Number: H22-00294) and Nepal Health
306 Research Council 305 British Columbia Clinical Research Ethics Board (UBC CREB Number: H22-00294) and Nepal Health
306 Research Council (NHRC Registration Number: 85/2022). Additionally, institutional certificates of
307 approval were obta 306 Research Council (NHRC Registration Number: 85/2022). Additionally, institutional certificates of
307 approval were obtained from the respective clinical sites where blood samples were stored and tealth
308 (from UBC C 307 approval were obtained from the respective clinical sites where blood samples were stored and to
308 (from UBC Children's & Women's Research Ethics Board and from Mount Sagarmatha Polyclinic a
309 Diagnostic Center). 307 approval were obtained from the respective clinical sites where blood samples were stored and teste
308 (from UBC Children's & Women's Research Ethics Board and from Mount Sagarmatha Polyclinic and
309 Diagnostic Cente

311 Blood samples were collected by trained phlebotomists or clinical laboratory technologists from veins in 310 Blood sample
311 Blood samples were
312 the antecubital foss **Blood sample collection**
311 Blood samples were collected by t
312 the antecubital fossa or the dorsur
313 needles or butterfly needles direct 312 the antecubital fossa or the dorsum of the hand. In Canada, blood was drawn from blood collection
313 needles or butterfly needles directly into 4.0 mL vacuum blood collection tubes with K2 EDTA (BD
314 Vacutainer, Bec needles or butterfly needles directly into 4.0 mL vacuum blood collection tubes with K2 EDTA (BD
314 Vacutainer, Becton, Dickinson and Company). In Nepal, blood was drawn from hypodermic needles
315 Syringes, and immediate 9313 needles or butterfly needles directly into 4.0 mL vacuum blood collection tubes with K2 EDTA (BD
314 Vacutainer, Becton, Dickinson and Company). In Nepal, blood was drawn from hypodermic needles into
315 syringes, and syringes, and immediately transferred to 3.0 mL disposable non-vacuum blood collection tubes with K3
316 EDTA (AV LabotUbe, AV Consumables). Blood samples were stored in a refrigerator at 4°C. Before
317 Iunning any tests, 316 EDTA (AV LabotUbe, AV Consumables). Blood samples were stored in a refrigerator at 4°C. Before
317 munning any tests, blood samples were placed at room temperature for at least 30 minutes, and the
318 blood tubes were running any tests, blood samples were placed at room temperature for at least 30 minutes, and the 318 blood tubes were repeatedly inverted or placed in rotary mixers to gently mix the separated plasma
318 minutes were repeatedly inverted or placed in rotary mixers to gently mix the separated plasma 318 blood tubes were repeatedly inverted or placed in rotary mixers to gently mix the separated plasma and

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

-
-
- settled blood cells. The blood samples were de-identified and associated with unique participant codes,
320 which were used as references for the blood tests and analyses. For the automated sickling test,
321 samples were
- 321 samples were prepared and imaged 1.4 ± 0.9 days (mean ± standard deviation) after blood collection,
322 and the maximum time between blood collection and imaging was 2 days in Nepal and 4 days in Canad
323 **Sample prep** 322 and the maximum time between blood collection and imaging was 2 days in Nepal and 4 days in Canada.
323 **Sample preparation for automated sickling test**
324 The sickling test is a well-established and commonly used scr

Sample preparation for automated sickling test
324 The sickling test is a well-established and commonly used screenir
325 hemoglobin S (HbS), but is not traditionally used to distinguish bet
326 cell disease (SCD)^{7,13}.

- 324 The sickling test is a well-established and commonly used screening technique to detect the presence of
325 hemoglobin S (HbS), but is not traditionally used to distinguish between sickle cell trait (SCT) and sickle
- 325 hemoglobin S (HbS), but is not traditionally used to distinguish between sickle cell trait (SCT) and sickle
326 cell disease (SCD)^{7,13}. In our sample preparation method for the sickling test, red blood cells formed a
- 326 cell disease (SCD)^{7,13}. In our sample preparation method for the sickling test, red blood cells formed a
327 monolayer with minimum overlap and adequate spacing for high-throughput imaging and subsequent
328 image pr
- cell disease (SCD)^{7,13}. In our sample preparation method for the sickling test, red blood cells formed a

monolayer with minimum overlap and adequate spacing for high-throughput imaging and subsequent

image processing.

-
- 328 image processing.
329 The sample preparation included the following steps:
329 1 Blood samples stared in EDTA tubes was taken aut of starses (at 4°C) and algoed at ream.
- 329 The sample prepar
330 1. Blood sam 1. Blood samples stored in EDTA tubes were taken out of storage (at 4°C) and placed at room
331 temperature for at least 30 minutes.
332 2. The reagent, 2% (w/w) sodium metabisulphite mixed in distilled water, was freshly
- 1. Samples of the temperature for at least 30 minutes.
1932 1. Blood samples in Europa store in Europa stores in EUTA tubes 2. The reagent, 2% (w/w) sodium metabisulphite mixed in distilled water, was freshly prepare
1933 2. The reagent, 2% (w/w) sodium metal
333 and used up to around 3 hours after province and used up to around 3 hours after province and used the material of the set of the material of the material of the material of the ma 333 and used up to around 3 hours after preparation. The reagent helped create a hypoxic
334 and used up to around 3 hours after preparation. The reagent helped create a hypoxic
335 3. The separated plasma and settled bloo
- 334 and use of around 3 hours and used up to around 3 hours after preparated plasma and settled blood cells were gently mixed by inverting the tube of the readers and settled blood cells were gently mixed by inverting the 335 3. The separated plasma and settled blood
336 it in a rotary mixer.
337 4. Whole blood and the reagent were pipe
- 336 336 it in a rotary mixer.
337 4. Whole blood and the reagent were pipetted at a 1:2 volume ratio (*e.g.* 150 µL of whole blood :
338 300 µL of reagent) into a separate tube or vial, and mixed by gentle inversions or i 337 $\begin{array}{r} 4. \text{ Whole blood and th} \\ 338 \text{ } 300 \text{ }\mu\text{L of reagent} \text{)} \\ 339 \text{ } \text{mixer.} \end{array}$ 338 300 µL of reagent) into a separate tube or vial, and mixed by gentle inversions or in a rotary
339 mixer.
340 5. A drop of the mixture of blood and reagent (3 µL to 3.3 µL) was pipetted onto a glass
- 339 mixer.
340 5. A drop of the mixture of blood and reagent (3 µL to 3.3 µL) was pipetted onto a glass
341 microscope slide, (VWR Vistavision 3" x 1" x 1 mm Microscope Slides, Cat. No. 16004-430). 340 5. A drop
341 micros
342 6. A micro 341 microscope slide, (VWR Vistavision 3" x 1" x 1 mm Microscope Slides, Cat. No. 16004-
342 6. A microscope coverslip (Fisherbrand Microscope Cover glass, 18 mm x 18 mm x 1 mm
343 Fisher Scientific, Pittsburgh, PA, USA) w
-
- 342 6. A microscope coverslip (Fisherbrand Microscope Cover glass, 18 mm x 18 mm x 1 mm, 1254
343 Fisher Scientific, Pittsburgh, PA, USA) was gently placed on top of the drop of blood and rea
344 to spread the mixture unif Fisher Scientific, Pittsburgh, PA, USA) was gently placed on top of the drop of blood and reagent
to spread the mixture uniformly. The coverslip was gently lowered onto the mixture with the aid
of a toothpick to spread the
- 344 to spread the mixture uniformly. The coverslip was gently lowered onto the mixture with the aid
345 of a toothpick to spread the mixture while minimizing the formation of bubbles. The size of the
346 coverslip (18 mm x
-
- of a toothpick to spread the mixture while minimizing the formation of bubbles. The size of the
346 coverslip (18 mm x 18 mm) was sufficient to spread the selected volume of the mixture (around
347 3 µL) uniformly, forming
-
- 346 coverslip (18 mm x 18 mm) was sufficient to spread the selected volume of the mixture (around
3 pm 3 pm 3 mm) was sufficient to spread the selected volume of the mixture (around
3 pm 3 pm 3 mm) was sufficient to spread coverslip (18 mm x 18 mm) was sufficient to spread the selected volume of the mixture (around
347 3 µL) uniformly, forming a monolayer of cells and with minimal leakage from the coverslip
348 edges. A coverslip of a differ edges. A coverslip of a different size requires a different volume of the mixture to be dispensed. 348 edges. A coverslip of a different size requires a different volume of the mixture to be dispensed.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

- 349 7. The edges of the coverslip were sealed with a mixture of Vaseline, Lanolin and Parrafin (VALAP)
350 at a 1:1:1 mass ratio³⁹. The VALAP was melted in a glass petri dish placed on an electric hot plate
351 at a temp VALAP and spread it on the edges of the coverslip. The VALAP solidified within a few seconds on
353 the coverslip and microscope slide to seal the mixture of blood and reagent.
354 . The process was duplicated for each sli
-
- VALAP and spread it on the edges of the coverslip. The VALAP solidified within a few seconds of
353 the coverslip and microscope slide to seal the mixture of blood and reagent.
354 8. The process was duplicated for each sl 353 the coverslip and microscope slide to seal the mixture of blood and reagent.
354 8. The process was duplicated for each slide for the same blood sample, such that there were two
355 coverslips on each slide. 354 8. The process was duplicated for each slide for the same blood sample, such the coverslips on each slide.
355 the sample preparation method for the sickling test from previous studies^{7,13} was mo

coverslips on each slide.
356 8. The sample preparation method for the sickling test from previous studies^{7,13} was modified to make it
357 3. suitable for imaging. Firstly, larger volumes of blood and reagent (150 µL : 3 355 coverslips on each slide. The sample preparation method for the sickling test from previous studies^{7,13} was modified to make it
suitable for imaging. Firstly, larger volumes of blood and reagent (150 μ L : 300 μ L) were mixed in a tube
or a 358 or a vial, instead of mixing a small drop of blood with a small drop of reagent on the glass slide. Mixing
359 the contents in a tube was more consistent than mixing them on the glass slide. Secondly, the volume
360 an 359 the contents in a tube was more consistent than mixing them on the glass slide. Secondly, the volume
360 ratio of blood to reagent was chosen as 1:2 (instead of the original 1:1 ratio) to avoid crowded cells and
361 ro 350 ratio of blood to reagent was chosen as 1:2 (instead of the original 1:1 ratio) to avoid crowded cells ane
361 rouleaux formation. Additionally, an inert and non-toxic sealant, VALAP, was used instead of nail
362 lacqu 361 rouleaux formation. Additionally, an inert and non-toxic sealant, VALAP, was used instead of nail
362 lacquers, which can contaminate the sample and sometimes created ghost cells (cells that have low
363 contrast in im 362 lacquers, which can contaminate the sample and sometimes created ghost cells (cells that have localized and sometimes created ghost cells (cells that have localized and sometimes of nail of nail of nail of nail of nail 363 contrast in images, due to negligible hemoglobin content and ruptured cell membranes³²) at the
364 periphery of the coverslip. Lastly, imaging was performed at 2 hours after sample preparation, while
365 samples were contrast in images, due to negligible hemoglobin content and ruptured cell membranes³⁴) at the
364 beriphery of the coverslip. Lastly, imaging was performed at 2 hours after sample preparation, w
365 samples were kept at 365 samples were kept at room temperature (20-25°C), which ensured that most of the cells for individuals
366 with SCD sickled. We found that temperature affects the rate of sickling – increasing the temperature
367 increa 366 with SCD sickled. We found that temperature affects the rate of sickling – increasing the temperature
367 increased the rate of sickling (Figures S2-S8 in Supplementary information). Imaging could potentially be
368 do 367 increased the rate of sickling (Figures S2-S8 in Supplementary information). Imaging could potentially
368 done earlier than 2 hours (e.g. 30 minutes to an hour) if samples were incubated at a higher
369 temperature (368 done earlier than 2 hours (e.g. 30 minutes to an hour) if samples were incubated at a higher
369 temperature (e.g. 37 °C), but temperature incubation was not chosen for this study due to the added
370 complexity and r 369 done earlier than 2 hours (e.g. 30 minutes to an hour) if samples were incubated at a higher
369 domenature (e.g. 37 °C), but temperature incubation was not chosen for this study due to the
370 complexity and requirem 369 temperature (*e.g.* 37 °C), but temperature incubation was not chosen for this study due to the complexity and requirement for a well-functioning incubator, which may not be accessible in remote/rural or low-resource s

373 The sealed wet preparation of blood mixed with 2% sodium metabisulphite was imaged with a low-cost **Automated high-throughput microscopy using Octopi**
373 The sealed wet preparation of blood mixed with 2% sodium metabisulphite was imaged with a low-
374 automated microscopy platform, Octopi (Open configurable high-throu **Automated high-throughput microscopy using Octopi**
373 The sealed wet preparation of blood mixed with 2% sodium metabisulphite
374 automated microscopy platform, Octopi (Open configurable high-throughpin
375 infectious di 374 automated microscopy platform, Octopi (Open configurable high-throughput imaging platform for
375 infectious disease diagnosis in the field)²⁶. An infinity corrected 20x magnification objective lens
376 (Olympus UPLF 375 infectious disease diagnosis in the field)²⁶. An infinity corrected 20x magnification objective lens
376 (Olympus UPLFLN 20x/0.5) was connected through a tube lens to a monochromatic camera (MER2
377 1220-32U3M, Dahe infectious disease diagnosis in the field)²⁶. An infinity corrected 20× magnification objective lens
376 (Olympus UPLFLN 20x/0.5) was connected through a tube lens to a monochromatic camera (MER2-
377 1220-32U3M, Daheng 1220-32U3M, Daheng Imaging). The monochromatic camera had a higher resolution than that of an equivalent color camera, and was sufficient (pixel size: $1.85\mu m$) for characterizing the morphology of \mathcal{S}_1 equivalent color camera, and was sufficient (pixel size: 1.85, \mathcal{S}_2 of characterizing the morphology of characterizing the morphology of characterizing the morphology of characterizing the morphology of cha

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

379 unstained cells in the prepared blood films. The microscope assembly included a 60 mm × 60 mm
380 motorized XY translational stage (HDS-U-XY6060SN, Heidstar Co., Ltd.) for automated slide scanning,
381 and a piezoelect 381 and a piezoelectric actuator to move the optical assembly for automated focusing. An LED matrix arrailluminated the sample, and the illumination intensity, timing and number of active LEDs were
383 programmatically con 382 illuminated the sample, and the illumination intensity, timing and number of active LEDs were
383 programmatically controlled. All the functionality of the microscope, such as the computational
384 illumination, image 383 programmatically controlled. All the functionality of the microscope, such as the computationa
384 illumination, image capture, motorized slide translation and autofocusing, were controlled usir
385 python-based graphi 384 illumination, image capture, motorized slide translation and autofocusing, were controlled using
385 python-based graphical user interface (GUI), operated in Linux.
386 The field of view (FOV) of each image was 3,000 p 385 illumination, include the temporal of the temporal of temporal state translation. In the field of view (FOV) of each image was 3,000 pixels by 3,000 pixels, corresponding to 0.9 mm by
387 in the field of view (FOV) of 386 For the field of view (FOV) of each image was 3,000 pixels by 3,000
387 The field of view (FOV) of each image was 3,000 pixels by 3,000
388 Fight halves of the LED matrix for the individual images, so that

386 The field of view (FOV) of each image was 3,000 pixels by 3,000 pixels, corresponding to 0.9 mm by
387 0.9 mm. At each sample location, an image pair was captured, by sequentially illuminating the left and
388 right ha 388 right halves of the LED matrix for the individual images, so that the image pair was combined into a
389 higher contrast image (discussed later in 'DPC image processing'). For each coverslip, a 15 by 15 grid
390 image 389 higher contrast image (discussed later in 'DPC image processing'). For each coverslip, a 15 by 15 grid
390 image pairs or 225 image pairs were captured covering most of the area of the coverslip (with no
391 overlap be 390 image pairs or 225 image pairs were captured covering most of the area of the coverslip (with no
391 overlap between adjacent FOVs), which took roughly 4 minutes including regular autofocusing after
392 every 3 image p 391 overlap between adjacent FOVs), which took roughly 4 minutes including regular autofocusing aft
392 every 3 image pairs. For each participant, 6 coverslips (3 slides prepared in Nepal) or 12 coverslips
393 slides prepa Every 3 image pairs. For each participant, 6 coverslips (3 slides prepared in Nepal) or 12 coverslips (6 slides prepared in Canada) were imaged 2 hours after sample preparation. Some coverslips were imaged 2 minutes right 393 slides prepared in Canada) were imaged 2 hours after sample preparation. Some coverslips were ima
394 right after sample preparation, and at different time intervals (*e.g.* at configurations such as 1 hour, 3
395 hour slides prepared in Canada) were imaged 2 hours after sample preparation. Some coverslips were imaged
394 right after sample preparation, and at different time intervals (*e.g.* at configurations such as 1 hour, 3
395 hours 395 hours, 4 hours, etc.). The series imaging was also captured for some participants (e.g. 1000 image pairs
396 captured every 3 seconds) to visualize the sickling process of red blood cells with different HbS
398 and mac

- 396 captured every 3 seconds) to visualize the sickling process of red blood cells with different HbS
397 concentrations. The images captured 2 hours after sample preparation were used for statistica
398 and machine learni 397 concentrations. The images captured 2 hours after sample preparation were used for statistical
398 and machine learning classification discussed here.
399 **Reference or gold standard test** 398 and machine learning classification discussed here.
399 **Reference or gold standard test**
399 Hemoglobin high performance liquid chromatography (Hb HPLC) is one of the standard clinical methods
-

399 **Reference or gold standard test**
100 Hemoglobin high performance liquid chromatograp
101 Lused for detecting sickle cell disease, B-thalassemia Reference or gold standard test

400 Hemoglobin high performance liquid chromatography (Hb HPLC) is one of the standard clinical method

401 used for detecting sickle cell disease, β-thalassemia and other common hemoglobi

401 used for detecting sickle cell disease, β-thalassemia and other common hemoglobinopathies, and was
402 the reference test in Nepal and Canada⁷. All the blood samples were tested using the Hb HPLC
403 technique; the

-
-
- 402 the reference test in Nepal and Canada⁷. All the blood samples were tested using the Hb HPLC
403 technique; the D10 Hemoglobin Testing System (Bio-Rad Laboratories Inc., California, USA) was used ir
404 Nepal, and t
- 402 the reference test in Nepal and Canada'. All the blood samples were tested using the Hb HPLC
403 technique; the D10 Hemoglobin Testing System (Bio-Rad Laboratories Inc., California, USA) was
404 Nepal, and the BioRad V
- Nepal, and the BioRad Variant II (Bio-Rad Laboratories Inc., California, USA) was used in Canada. The
405 the interpretations of the Hb HPLC results by medical laboratory technologists or hematopathologists serve
406 as gr 114 114 Nepal, and the Biotham Variant II (Bioman Laboratory Canonics Inc., Canonics) with the Biomannia The
105 Interpretations of the BioRad Variant II (Bio-Rad Laboratory technologists or hematopathologists ser
107 Inst 405 interpretations of the Hb HPLC results by medical laboratory technologists or hematopathologists servention
406 as ground truth or diagnosis for the participants and was used for morphological characterization and
407 406 as ground truth or diagnosis for the participants and was used for morphological characterization and

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

408 Differential phase contrast (DPC) image processing
409 The raw images from Octopi included image pairs illuminated from opposite illumination angles – one
410 image illuminated by the left half (with intensity I_L) 410 image illuminated by the left half (with intensity I_L), and the other image illuminated by the right half
411 (with intensity I_R), of the programmable LED matrix. By normalizing the difference between the two
412 410 Image indifferent objects half (with intensity I_L), and the other image indifference between the two
411 (with intensity I_R), of the programmable LED matrix. By normalizing the difference between the two
413 compu 411 (with intensity I_R), of the programmable LED matrix. By normalizing the difference between the two
412 images, the intensity of differential phase contrast (DPC) image $I_{DPC} = 0.5 + (I_L - I_R)/(I_L + I_R)$ wa
413 computed on a that images, the intensity of differential phase contrast (DFC) image $t_{DPC} = 0.5 + (t_L - t_R) / (t_L + t_R)$ was

413 computed on a pixel-by-pixel basis. DPC imaging captures the phase gradient information from the two

414 images $(1 - \frac{1}{R}) / (1 - \frac{1}{R})$ 144 images with opposite illumination angles, and does not rely on specialized objectives for phase
115 imaging⁴⁰. The blood cells in DPC images had sufficient contrast for morphological characterization (as
116 shown in 415 imaging⁴⁰. The blood cells in DPC images had sufficient contrast for morphological characterizat
416 shown in Fig. 1), without the need for staining, which is typically required for peripheral blood s
417 The DPC pro imaging^{-v}. The blood cells in DPC images had sufficient contrast for morphological characterization (as
416 shown in Fig. 1), without the need for staining, which is typically required for peripheral blood smears³
417 shown in Fig. 1), without the need for staining, which is typically required for peripheral blood smears³².
417 The DPC processing and most of the following image analyses were performed on a computing cluster
418 . (Ced 418 (Cedar, Compute Canada, Digital Research Alliance of Canada) due to the large scale of the image
419 dataset, which benefitted from computational resources and parallel computing on the cluster (mostly
420 using GPUs). dataset, which benefitted from computational resources and parallel computing on the cluster (m
420 using GPUs).
421 **Segmentation of blood cells using Cellpose 2.0** dataset, which benefitted from computational resources and parallel computing on the cluste

420 using GPUs).
 Segmentation of blood cells using Cellpose 2.0

8 Blood cells in the differential phase contrast (DPC) images

421 Segmentation of blood cells using Cellpose 2.0
422 Blood cells in the differential phase contrast (DPC) images were se
423 segmentation algorithm, Cellpose 2.0³⁰, where a pre-trained neuro **Segmentation of blood cells using Cellpose 2.0**
422 Blood cells in the differential phase contrast (DPC) images were se
423 segmentation algorithm, Cellpose 2.0³⁰, where a pre-trained neura
424 tuned using a human-in-th 423 segmentation algorithm, Cellpose 2.0³⁰, where a pre-trained neural network model (Cyto) was
424 tuned using a human-in-the-loop approach. The human-in-the-loop approach used 125 image
425 (1,500 pixels × 1,500 pixel tuned using a human-in-the-loop approach. The human-in-the-loop approach used 125 image segments

425 (1,500 pixels × 1,500 pixels; 450 μ m × 450 μ m) from multiple donors and a recursive training approach.

426 Each 427 the neural network and adding missing outlines of cells. The human-in-the-loop or iterative retraining
428 approach greatly reduces the number of user annotations required because annotations are corrected 428 approach greatly reduces the number of user annotations required because annotations are corrected
429 in each retraining cycle, which iteratively improves the neural network model³⁰. The default pre-trainec 427 the neural network and adding missing outlines of cells. The human-in-the-loop or iterative retraining
428 approach greatly reduces the number of user annotations required because annotations are corrected
429 in each approach greatly reduces the number of user annotations required because annotations are corrected
429 the each retraining cycle, which iteratively improves the neural network model³⁰. The default pre-traine
430 the ural in each retraining cycle, which iteratively improves the neural network model³⁰. The default pre-trained
130 approach greatly relies 2.0 already segmented round cells well, but the human-in-the-
131 loop approach was nec in each retraining retraining the unity of the human-in-the-
in-the-
ioop approach was necessary to segment sickle cells, to avoid segmenting platelets, artifacts (*e.g.*
bubbles), and incomplete or obscured cells (*e.g.* 430 neural-network model, Cyto, in Cellpose 2.0 already segmented round cells well, but the human-in-thebubbles), and incomplete or obscured cells (*e.g.* overlapped cells and cells at the edges of the image).

433 Cell segmentation was the most computationally expensive process out of all the image processing

434 tasks, ta 433 Cell segmentation was the most computationally expensive process out of all the image processing
434 tasks, taking around 1-2 minutes for segmentation of around 4,000-6,500 cells per image using GPUs.
435 However, the 134 tasks, taking around 1-2 minutes for segmentation of around 4,000-6,500 cells per image using GPU
435 However, the overall computation time was significantly reduced by running parallel jobs on the Ce
436 cluster. 435 However, the overall computation time was significantly reduced by running parallel jobs on the Cedar
436 cluster. 436 cluster, the overall computation time was significantly reduced by running parallel jobs on the Cedar on the Cedar

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Calculating morphological and intensity parameters
The outlines of segmented cells were saved by Cellpose 2.0 as text files, which were read by an image
processing software, ImageJ⁴¹ (or FIJI⁴²). The outlines were ov processing software, ImageJ⁴¹ (or FIJI⁴²). The outlines were overlaid on the corresponding DPC images in
440 ImageJ to calculate morphological and intensity parameters of each cell. The parameters were
441 measured usi ImageJ to calculate morphological and intensity parameters of each cell. The parameters were

141 measured using ImageJ on the Cedar cluster, without the GUI or in "headless" mode. A total of

142 different morphological a 441 measured using ImageJ on the Cedar cluster, without the GUI or in "headless" mode. A total of
442 different morphological and intensity parameters were extracted for each cell, including basic
443 morphological paramet different morphological and intensity parameters were extracted for each cell, including basic
morphological parameters (e.g. area, perimeter, minor axis, major axis, etc.), non-dimensional
morphological parameters (e.g. c morphological parameters (e.g. area, perimeter, minor axis, major axis, etc.), non-dimensional

morphological parameters (e.g. circularity, aspect ratio, eccentricity, etc.), and intensity-based

parameters (e.g. mean inte morphological parameters (e.g. area, perimeter, minor axis, major axis, etc.), non-dimensional
444 morphological parameters (e.g. circularity, aspect ratio, eccentricity, etc.), and intensity-based
445 parameters (e.g. mea parameters (e.g. mean intensity, skewness, kurtosis, etc.). Furthermore, 8 basic morphological
parameters (e.g. mean intensity, skewness, kurtosis, etc.). Furthermore, 8 basic morphological
445 parameters were normalized b parameters (e.g. mean intensity, skewness, kurtosis, etc.). Furthermore, 8 basic morphological
parameters were normalized by the mean values per image (*e.g.* normalized area, normalized
447 perimeter, *etc.*). A complete parameters were normalized by the mean values per image (e.g. normalized area, normalized
447 perimeter, *etc.*). A complete list of these parameters is provided in Supplementary information
448 for each image (morphologic 448 for each image (morphological and intensity parameters is provided in Supplementary information. The data
448 for each image (morphological and intensity parameters for every cell in the image) was stored in a
449 comm for each image (morphological and intensity parameters for every cell in the image) was stored in

comma separated variable or .csv files, which was used for further processing (*e.g.* using MATLAB

programs).
 Morphologi

452 Normalized frequency distribution of each morphological and intensity parameter was calculated using 451 **Morphol**
452 Normalized
453 the *histcoul* **Morphological characterization**
452 Normalized frequency distribution of each n
453 the *histcounts* function in MATLAB, where the number of elements in the bin, c_i , to the tot 453 the *histcounts* function in MATLAB, where the value in each bin $v_i = c_i/N$ represented the ratio of the
454 number of elements in the bin, c_i , to the total number of elements in the data, N. The frequency
455 distrib 154 number of elements in the bin, c_i , to the total number of elements in the data, N. The frequency
155 distribution, representing relative probability of each morphological parameter, was calculated at
156 different l c_i /*N* represented the ratio of the
the data, *N*. The frequency
parameter, was calculated at
participant or donor level, and the distribution, representing relative probability of each morphological parameter, was calculated at
456 distribution, representing relative probability of each morphological parameter, was calculated at
457 group or class different levels or scales – at the image level, the coverslip level, the participant or donor level, and
457 group or class level. For the analysis presented here, each frequency distribution was divided into
458 bins. Th 457 group or class level. For the analysis presented here, each frequency distribution was divided into 30
458 bins. The data for Canada and Nepal, imaged at 2 hours after sample preparation and stored at room
459 temperat bins. The data for Canada and Nepal, imaged at 2 hours after sample preparation and stored at room
459 temperature, were combined to form 4 clinically relevant groups – AA, ABeta, AS, and SCD (including
460 SBeta and SS), bins. The data for Canada and Nepal, imaged at 2 hours after sample preparation and stored at room

temperature, were combined to form 4 clinically relevant groups – AA, ABeta, AS, and SCD (including

SBeta and SS), and cl 149 SBeta and SS), and classification was performed on different combinations of these groups.
161 **Calculating statistical differences between different classes**
162 Differences between the frequency distributions of the

461 **Calculating statistical differences between different classes**
162 Differences between the frequency distributions of the 4 different groups were calculated in
163 using one-way analysis of variance (ANOVA) and a post **Calculating statistical differences between different classes**
162 Differences between the frequency distributions of the 4 different groups were calculated in MATI
163 using one-way analysis of variance (ANOVA) and a pos 1444 University of the frequency and a matrix of the 1 and 2 digital people in the 1 differences between the the
1463 Unit ions and a multipulate and MATLABA and a post-hoc multiple comparison test (MCT), using
1465 Univer 464 functions anova1 and multcompare. ANOVA compares the means of several groups and tests the
465 hypothesis that they are equal against the alternative that they are not, indicating that at least one
466 the means is dif 464 Functions anoval and marticompare. ANOVA compares the means of several groups and tests the
465 hypothesis that they are equal against the alternative that they are not, indicating that at least on
466 the means is dif 465 hypothesis that they are equal against the alternative that they are not, indicating that at least one
466 the means is different without specifying which pairs are different. MCT can be applied for a more 466 the means is different without specifying which pairs are different. MCT can be applied for a more

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

468 for 4 groups). The most conservative method for multiple comparison, the Scheffe's method, was
469 applied as it is suitable for exploratory data analysis⁴³. MCT with Scheffe's method was used to calcula
470 p-values applied as it is suitable for exploratory data analysis⁴³. MCT with Scheffe's method was used to cal
470 p-values for all pair-wise combinations of the 4 groups at each bin of the frequency distribution of
471 morphologi applied as it is suitable for exploratory data analysis⁴³. MCT with Scheffe's method was used to calculate
470 p-values for all pair-wise combinations of the 4 groups at each bin of the frequency distribution of each
471 471 morphological parameter. The bins or regions of all non-dimensional morphological parameters that
472 eralted in the lowest p-values (highest differences) for each combination and for all combinations
473 (considering 172 morphological parameters in a state of regions of an international morphological parameters into
172 mesulted in the lowest p-values (highest differences) for each combination and for all combinations
174 feature selec 473 (considering the geometric mean of p-values) were highlighted and also selected for classification v
474 feature selection.
475 **Morphology-based machine learning classification** 474 (considering the geometric means of p-values) were ingingited and also selected for classification
475 **Morphology-based machine learning classification**
476 The frequency distribution at the coverslip level (where eac

feature selection.
 475 Morphology-based machine learning classification

476 The frequency distribution at the coverslip level (where each coverslip

477 describing the frequency of a parameter for all the cells under a **Morphology-based machine learning classification**
476 The frequency distribution at the coverslip level (where each coverslip
477 describing the frequency of a parameter for all the cells under a covers
478 was used for c describing the frequency of a parameter for all the cells under a coverslip for a particular participant,

478 was used for classification of the different groups. Based on statistical analysis and due to the

479 robustne 478 was used for classification of the different groups. Based on statistical analysis and due to the
479 robustness of non-dimensional parameters, 19 non-dimensional morphological parameters were
480 selected out of the t 479 robustness of non-dimensional parameters, 19 non-dimensional morphological parameters words.
480 selected out of the total 40 parameters, as described in Supplementary information. The DPC
481 were not directly used fo 480 selected out of the total 40 parameters, as described in Supplementary information. The DPC ima
481 were not directly used for classification, but the morphological parameters were used instead bec
482 classification u were not directly used for classification, but the morphological parameters were used instead because
classification using the frequency distribution of these parameters was computationally much less
resource-intensive and directly used in the more interactions, and the morphological parameters was computationally much less

resource-intensive and was also more interpretable than image-based classification – for instance, the

frequency dist 483 resource-intensive and was also more interpretable than image-based classification – for instance,
484 frequency distribution of morphological parameters for classification can be visualized and compar
485 statisticall 484 frequency distribution of morphological parameters for classification can be visualized and compared
485 statistically to check for differences between different classes.
486 Different groups were considered for classi

487 considered for screening only HbS without β -thalassemia (referred to as 3 groups or 3Gp). In this case, 486 Different groups were considered for classification: i) 3 groups (AA & ABeta, AS, SCD) typically
487 considered for screening only HbS without β-thalassemia (referred to as 3 groups or *3Gp*). In th
488 β-thalassemia 488 B-thalassemia trait (ABeta) was not identified separately from normal (AA), thus 3Gp classification is
489 suitable either in regions with low prevalence of β-thalassemia, or in regions with high β-thalassemia
490 pr 488 β-thalassemia trait (ABeta) was not identified separately from normal (AA), thus 3Gp classification is
489 suitable either in regions with low prevalence of β-thalassemia, or in regions with high β-thalassemia
490 pr 489 suitable either in regions with low prevalence of β-thalassemia, or in regions with high β-thalassemia
490 prevalence with supplemental low-cost screening tests for β-thalassemia, *e.g.* NESTROFT⁴⁴. ii) 3 group
491 490 prevalence with supplemental low-cost screening tests for β-thalassemia, *e.g.* NESTROFT⁴⁴. ii) 3 group
491 (AA, ABeta & AS, SCD) relevant for screening for both HbS and β-thalassemia, which combined the tra
492 con (AA, ABeta & AS, SCD) relevant for screening for both HbS and β-thalassemia, which combined the trait
conditions together and the SCD conditions together (referred to as 3 groups for screening or 3GpSc).
The trait conditi 492 conditions together and the SCD conditions together (referred to as 3 groups for screening or 3GpSc).
493 The trait conditions, β-thalassemia trait (ABeta) and sickle cell trait (AS), were combined in 3GpSc
494 becaus 492 conditions together and the SCD conditions together (referred to as 3 groups for screening or 3GpSc).
493 The trait conditions, β-thalassemia trait (ABeta) and sickle cell trait (AS), were combined in 3GpSc
495 confi because of similar outcomes for the two asymptomatic groups after screening, *i.e.* follow-up
495 Confirmatory tests and genetic counselling for participants of reproductive age. iii) 4 clinically confirmatory tests and genetic counselling for participants of reproductive age. iii) 4 clinically relevant $\frac{1}{2}$ confirmation generic counselling for participants of reproductive age. iii) 4 clinically relevants of relevants of $\frac{1}{2}$

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

more the property and the state and their similar and the settimate and state and their similarity morphologies and clinical outcomes^{3,5,7} (referred to as 4 groups or 4Gp).
498 The Classification Learner App in MATLAB (u morphologies and clinical outcomes^{3,5,7} (referred to as 4 groups or 4Gp).
498 The Classification Learner App in MATLAB (using MATLAB 2023a) was use
499 different models or classifiers (based on support vector machine, de different models or classifiers (based on support vector machine, decision tree, ensemble, neural
199 The Classication Learner App in Mathematics of the performance of the performance of 3023
1991 The performation and 30:2 499 b. 300 network, k-nearest neighbors, Naïve Bayes, and discriminant analysis – complete list in Supplemer
499 different models of training and testing data was used such that data f
499 each participant was either in th 500 network, k-nearest neighbors, Naïve Bayes, and discriminant analysis – complete list in Supplementary
501 information). An 80:20 participant-wise split of training and testing data was used such that data from
502 each EXECT INFORMATION). AN EXECT PRINCIPAL THE SPIN OF A RAING AND THE MORE THE CRISING THE CHINESE.
503 between balanced by up-sampling or randomly repeating some data for the minority classes, such that all
504 between that So the participant was either in the training split of the testing split, to prevent bias the training the classes and that all the classes had an equal number of images. Balancing the classes was important to remove bias 504 the classes had an equal number of images. Balancing the classes was important to remove bias towar
505 the majority class when training the models and when calculating performance metrics. During training
506 10-fold the majority class when training the models and when calculating performance metrics. During training,
506 10-fold cross-validation was performed to reduce overfitting of the training dataset. As an example for
507 the num 506 10-fold cross-validation was performed to reduce overfitting of the training dataset. As an example for
507 the numbers of coverslips used for training and testing datasets, for the top classifier (subspace
508 discrim 507 the numbers of coverslips used for training and testing datasets, for the top classifier (subspace
508 discriminant) for classification into 4 groups, the mean (and standard deviation) numbers for training
509 (pre-bal 508 discriminant) for classification into 4 groups, the mean (and standard deviation) numbers for tra
509 (pre-balancing) was 798.8 (20.2) for all groups, 169.7 (6.0) for AA, 108.8 (0.4) for ABeta, 266.4 (6
510 AS, and 253 509 (pre-balancing) was 798.8 (20.2) for all groups, 169.7 (6.0) for AA, 108.8 (0.4) for ABeta, 266.4 (6.4) for
510 AS, and 253.9 (7.4) for SCD, and for testing (pre-balancing) was 202.2 (20.2) for all groups, 42.3 (6.0) f 510 AS, and 253.9 (7.4) for SCD, and for testing (pre-balancing) was 202.2 (20.2) for all groups, 42.3 (6.0) for
511 AA, 30.2 (0.4) for ABeta, 66.6 (6.4) for AS, and 63.1 (7.4) for SCD.
512 The performance metrics for val

511 AA, 30.2 (0.4) for ABeta, 66.6 (6.4) for AS, and 63.1 (7.4) for SCD.
512 The performance metrics for validation (*e.g.* validation accuracy) obtained during training are not
513 presented here, and only the performance 41 AA, 30.2 (0.4) for ABeta, 66.6 (6.4) for AS, and 63.1 (7.4) for SCD.
512 The performance metrics for validation (*e.g.* validation accuracy) obtained during training are not
513 presented here, and only the performance First The performance metrics for validation (e.g. validation accuracy) obtained during training are not
513 presented here, and only the performance metrics for testing (e.g. testing accuracy) are presente
515 **Performan** 513 presented here, and only the performance metrics for testing (e.g. testing accuracy) are presented. In
514 general, validation accuracy was higher than testing accuracy.
516 The sensitivity (or recall). Sens = $TP/(TP + FN)$

515 **Performance evaluation metrics**
516 The sensitivity (or recall), $Sens = TP/(TP + FN)$, is related to
517 values, and is the ability to correctly classify an individual belor **Performance evaluation metrics**
516 The sensitivity (or recall), $Sens = TP/(TP +$
517 values, and is the ability to correctly classify a
518 specificity, $Spec = TN/(TN + FP)$, is related Sto The sensitivity (or recall), $5ehs = IT/(IT+TN)$, is related to true positive (11) and false negative (11)

517 values, and is the ability to correctly classify an individual belonging to a certain class or group. The

518 s 518 specificity, $Spec = TN/(TN + FP)$, is related to true negative (TN) and false positive (FP) values, and the ability to correctly classify an individual not belonging to a certain class or group. Other perform
520 metrics, such $\frac{1}{10}$ specificity, $\frac{1}{2}$ because $\frac{1}{10}$ is related to true negative (TN) and raise positive (FT) values, and is

519 the ability to correctly classify an individual not belonging to a certain class or group. 520 metrics, such as accuracy, positive predictive value (or precision), negative predictive value, and F1-
521 score, were also calculated and are tabulated for the top 5 classifiers in Supplementary information. For
522 521 score, were also calculated and are tabulated for the top 5 classifiers in Supplementary information
522 multiclass problems, the performance metrics can be calculated, per class or group, by comparing o
523 group agai 522 multiclass problems, the performance metrics can be calculated, per class or group, by comparing one
523 group against all others (also known as one vs. all or one vs. rest), and the metrics were macro-averaged
524 by 523 group against all others (also known as one vs. all or one vs. rest), and the metrics were macro-average
524 by taking the mean of values for all individual groups. 524 by taking the mean of values for all individual groups.

Section 2014 by taking the mean of values for all individual groups. 524 by taking the mean of values for all individual groups.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Classification metrics, repeatability and confidence intervals
526 To test the repeatability of the classifications and to obtain confidence intervals for t
527 metrics, all classification models were iteratively trained 527 metrics, all classification models were iteratively trained and tested using random participant-wise
528 of the data (80 : 20 for training : testing) for 1,000 independent iterations. For each iteration, all
529 evalua 528 of the data (80 : 20 for training : testing) for 1,000 independent iterations. For each iteration, all
529 evaluation metrics were calculated for the testing data set: accuracy, sensitivity or recall, specificity,
530 529 evaluation metrics were calculated for the testing data set: accuracy, sensitivity or recall, specific
530 positive predictive value or precision, negative predictive value, and F1-score calculated from the
531 confusi 530 positive predictive value or precision, negative predictive value, and F1-score calculated from the
531 confusion matrix, and the area under the curve (AUC) calculated from the receiver operating
532 characteristic (RO 530 positive predictive value or precision, negative predictive value, and F1-score calculated from the
531 confusion matrix, and the area under the curve (AUC) calculated from the receiver operating
532 characteristic (RO characteristic (ROC) curve for each class (using one vs. all method; Fig. 5). Macro-averaged va
533 these evaluation metrics were calculated to combine metrics from all classes. For all 1,000 ite
534 the mean and 95% confi 533 these evaluation metrics were calculated to combine metrics from all classes. For all 1,000 iterations
534 the mean and 95% confidence intervals (assuming normal distribution) were calculated for each
535 evaluation me 1334 the mean and 95% confidence intervals (assuming normal distribution) were calculated for each
535 evaluation metric and the macro-averaged metrics. Additionally, data from all 1,000 iterations were
536 aggregated to c Example 1944 the mean and 95% conductions (assuming normal distribution) were calculated for each example of the macro-averaged metrics. Additionally, data from all 1,000 iterations w
536 aggregated to calculate merged con 536 aggregated to calculate merged confusion matrices and ROC curves (individual class and macro-
537 averaged ROC curves).
538 **Open-access database**

S38 **Open-access dat**
539 In accordance with the
540 identified data (such as **538 Open-access database**

539 In accordance with the approved

540 identified data (such as de-ident

541 segmentation outlines, morphol

539 In accordance with the approved research protocols and informed consent from participants, de-

identified data (such as de-identified images of blood films from Octopi, and processed data such as

541 segmentation outlines, morphological parameters, *etc.*) were deposited in an online public repository,

542 Federat 541 Segmentation outlines, morphological parameters, etc.) were deposited in an online public repository,
542 Federated Research Data Repository (FRDR), an open-access repository hosted by the Digital Research
544 The data

539 In accordance with the approved research protocols and informed consent from participants, de-

Federated Research Data Research Data Repository (FRDR), and process defined in provided https://doi.org/10.20383/103.0916
544 The dataset contains all the raw and processed data, and can be used to reproduce the results
5 Alliance of Canada. The link to the open-access dataset is provided <u>https://doi.org/10.20383/103.0916</u>²⁴.
544 The dataset contains all the raw and processed data, and can be used to reproduce the results
545 pr presented here and also for further development of classification or morphological characterize
546 Sickle cell disease and β-thalassemia. The morphological and intensity parameters for data fron
547 And Canada used in th

546 sickle cell disease and β -thalassemia. The morphological and intensity parameters for data from Nepal
547 and Canada used in the current work (imaging at 2 hours at room temperature), and additional data fo
548 add 547 and Canada used in the current work (imaging at 2 hours at room temperature), and additional data fo
548 additional configurations (e.g. different time settings, temperature settings, and time series data) are
549 avai and Canada used in the current work (imaging at 2 hours at room temperature), and additional data fo
548 additional configurations (*e.g.* different time settings, temperature settings, and time series data) are
550 All th

additional comigurations (e.g. different time settings, temperature settings, and time series data) are
available publicly in FRDR, stored as .csv files.
550 All the associated code (written in Python, MATLAB, or shell) fo 549 available public, in FRDR, stored as the contract
550 all the associated code (written in Python, MA
551 also available online in a public Github reposit

551 also available online in a public Github repository (https://github.com/p-shrestha/erythroSight).

The associate online in a public Github repository (https://github.com/p-shrestha/erythroSight). 551 also available online in a public Github repository (https://github.com/p-shrestha/erythroSight).

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

Acknowledgements
553 We sincerely thank all the participants in the study for their invaluable blood samples; Ashik Gurung,
554 Mahesh Chaudhary, Ram Prabesh Tharu, Asmita Chaudhary, Sanjeev Chaudhary, and Shiva Gautam f 554 Mahesh Chaudhary, Ram Prabesh Tharu, Asmita Chaudhary, Sanjeev Chaudhary, and Shiva Gautam for the blood collection, tests and HPLC interpretation at Mount Sagarmatha Polyclinic and Diagnostic Center
555 Nepal; Dr. Myk 555 blood collection, tests and HPLC interpretation at Mount Sagarmatha Polyclinic and Diagnostic Center in
556 Nepal; Dr. Mykola Maydan for help with coordination, equipment setup and technical advice at the
557 pathology 556 Nepal; Dr. Mykola Maydan for help with coordination, equipment setup and technical advice at the
557 pathology lab at BC Children's Hospital; all the phlebotomists and staff at BC Children's Hospital and St
558 Paul's Nepal; Dr. Mykola Maydan for help with coordination, equipment setup and technical advice at the
557 pathology lab at BC Children's Hospital; all the phlebotomists and staff at BC Children's Hospital and St.
558 Paul's Hos Fathology lab at BC Chindren's Hospital_, and the phlebotomical and the philodrenic Hospital and Theorem (Feating
558 Paul's Hospital in Canada who helped with the study; Dinesh Raj Sapkota and Nura Basnet from Creating
5 559 Possibilities Nepal, and the UBC sickle cell team for helpful discussions; Dr. Roshan Chitrakar for
560 document translations; Erin Clary, Eugene Barsky, Jiarui Li, Paul Lesack, Tamanna Moharana, and Nick
561 Rochlin f 560 document translations; Erin Clary, Eugene Barsky, Jiarui Li, Paul Lesack, Tamanna Moharana, and Nick
561 Rochlin for helping set up the open-access dataset, cloud computing tools and data transfer protocols.
562 This r 561 Rochlin for helping set up the open-access dataset, cloud computing tools and data transfer protocols.
562 This research was undertaken, in part, with support from the Canada Research Chairs program, UBC
563 Health Inn 562 This research was undertaken, in part, with support from the Canada Research Chairs program, UBC
563 Health Innovation Funding Investment (HIFI) Awards, and the UBC Four Year Doctoral Fellowship (4YF)
564 program. The 563 Health Innovation Funding Investment (HIFI) Awards, and the UBC Four Year Doctoral Fellowship (4Y
564 program. The UBC Centre for Blood Research is home to the Naiman Vickars Endowment fund which
565 provided funds for From Health Innovation Funding Indonesia. (HIF) And the UEC CENTER PERMAN ELEMENT (HIF)
1964 – program. The UBC Centre for Blood Research is home to the Naiman Vickars Endowment fund which has
1966 – **Author contributions** 565 provided funds for this project.
566 **Author contributions**

566 **Author contributio**
567 **Pranav Shrestha: Conceptualiza** 566 **Author contributions**
567 **Pranav Shrestha: Conceptualization,
568 Original Draft, Writing - Review & Edi
569 Investigation, Writing - Review & Edi Pranav Shrestha**: Conceptualization, Methodology, Software, Formal analysis, Investigation, Writing -
568 Original Draft, Writing - Review & Editing, Visualization, Funding acquisition. **Hendrik Lohse**: Software,
569 Inve 568 Original Draft, Writing - Review & Editing, Visualization, Funding acquisition. Hendrik Lonse: Software,
569 Investigation, Writing - Review & Editing. **Christopher Bhatla**: Conceptualization, Methodology,
571 **Alzaki** 569 Investigation, Writing - Review & Editing. Christopher Bhatla: Conceptualization, Methodology,
570 Investigation, Writing - Review & Editing. Heather McCartney: Resources, Project administration
572 Project administrat 12571 Alzaki: Resources. Navdeep Sandhu: Resources, Project administration. Pradip Kumar Oli: Investigation,
1572 Project administration. Hongquan Li: Methodology, Software, Resources, Writing - Review & Editing.
1573 Manu 571 Alzaki: Resources: Navacep Sandhu: Resources, Project administration. Pradip Rumar Oli: Investigation,
572 Project administration. **Hongquan Li**: Methodology, Software, Resources, Writing - Review & Editing.
574 Method 110 Project administration. Hongquan Li: Methodology, Software, Resources, Writing - Review & Editing.
573 Manu Prakash: Methodology, Resources, Supervision, Writing - Review & Editing. Ali Amid:
575 Writing - Review & Edi 573 Manu Prakash: Methodology, Resources, Supervision, Writing Review & Editing. All Amid:
574 Methodology, Resources, Writing - Review & Editing. Rodrigo Onell: Conceptualization, Met
576 Hayley Merkeley: Conceptualizatio S74 Methodology, Resources, Withing - Review & Editing. Roungo Onen. Conceptualization, Methodology,
575 Mriting - Review & Editing. Nicholas Au: Conceptualization, Methodology, Writing - Review & Editing.
577 **Kapoor**: Co 575 Writing - Review & Editing. Nicholas Au: Conceptualization, Methodology, Writing - Review & Editing.
576 Hayley Merkeley: Conceptualization, Methodology, Resources, Writing - Review & Editing. Videsh
578 Conceptualizat 176 Hayley Merkeley: Conceptualization, Methodology, Resources, Writing - Review & Editing. Videsh
177 Kapoor: Conceptualization, Methodology, Writing - Review & Editing, Funding acquisition. Rajan Pande:
178 Conceptualiza 577 Kapoor: Conceptualization, Methodology, Writing Review & Editing, Funding acquisition. Rajan Funde:
578 Conceptualization, Methodology, Resources, Supervision. **Boris Stoeber**: Conceptualization,
580 acquisition. 578 Conceptualization, Methodology, Resources, Supervision. **Boris Stoeber**: Conceptualization,
579 Methodology, Formal analysis, Writing - Original Draft, Writing - Review & Editing, Supervisio
580 acquisition. 580 acquisition.
580 acquisition.
2. 580 acquisition.

-
- **Competing interests**

582 Hongquan Li and Manu Prakash are co-founders, and Pranav Shrestha is an employee, of Cephla Inc.,

583 which is a spin-out company from Stanford University, deploying Octopi globally for disease which is a spin-out company from Stanford University, deploying Octopi globally for disease diagnostics.
584 **References**
585 1. Kato, G. J. *et al.* Sickle cell disease. *Nat. Rev. Dis. Prim.* 4, 18010 (2018).

- 584 **References**
585 1. Kato, G. J. *et al.* Sickle cell disease. *Nat. Rev. Dis. Prim.* 4, 18010 (2018).
- **References**

585 1. Kato, G. J. *et al.* Sickle cell disease. Nat. Rev. Dis. Prim. 4, 18010 (2018).

586 2. Adepoju, P. Ghana takes on sickle-cell disease. *Lancet* 395, 402 (2020).

587 3. Piel, F. B., Steinberg, M. H. &
- 585 1. Kato, G. J. et al. Sickle cell disease. *Nut. Rev. Dis. FTML*. 4, 18010 (2018).
586 2. Adepoju, P. Ghana takes on sickle-cell disease. *Lancet* **395**, 402 (2020).
587 3. Piel, F. B., Steinberg, M. H. & Rees, D. C. S 586 2. Adepoja, P. Ghana takes on sickle-cell disease. *Lancet* 393, 402 (2020).
587 3. Piel, F. B., Steinberg, M. H. & Rees, D. C. Sickle Cell Disease. *N. Engl. J. N*
588 (2017).
- 588 (2017).
589 4. Rees, D. C., Williams, T. N. & Gladwin, M. T. Sickle-cell disease. Lancet **376**, 2018–2031 (2010).
590 5. Ware, R. E., de Montalembert, M., Tshilolo, L. & Abboud, M. R. Sickle cell disease. Lancet 390,
- 588 (2017). 590 5. Ware, R. E., de Montalembert, M., Tshilolo, L. & Abboud, M. R. Sickle cell disease. *Lancet* 390,
591 311–323 (2017).
592 6. Galanello, R. & Origa, R. Beta-thalassemia. *Orphanet J. Rare Dis.* 5, 11 (2010). 590 5. Ware, R. E., de Montalembert, M., Tshilolo, L. & Abboud, M. R. Sickle cell disease. *Luncet 350*,
591 311–323 (2017).
592 6. Galanello, R. & Origa, R. Beta-thalassemia. *Orphanet J. Rare Dis.* 5, 11 (2010).
-
- 592 6. Galanello, R. & O
593 7. Wild, B. J. & Bain
594 1. Louvis Practical H 593 7. Wild, B. J. & Bain, B. J. Investigation of Variant Haemoglobins and Thalassaemias. in Dacie and
594 Lewis Practical Haematology 282–311 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.00014-
595 X. 593 7. Wild, B. J. & Bain, B. J. Investigation of Variant Haemoglobins and Thalassaemias. in Ducle and
594 Lewis Practical Haematology 282–311 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.0001
596 8. Pauling, L., Itano
- 595 Lewis Fractical Haematology 262–311 (Elsevier, 2017). doi:10.1010/B978-0-7020-6696-2.00014
595 X. Pauling, L., Itano, H. A., Singer, S. J. & Wells, I. C. Sickle Cell Anemia, a Molecular Disease. Science
597 (80-.). 11 595 X. 8. Pauling, L., Itano, H. A., Singer, S. J. & Wells, I. C. Sickle Cell Anemia, a Molecular Disease. Science

597 (80-.). **110**, 543–548 (1949).

598 9. Frangoul, H. *et al.* CRISPR-Cas9 Gene Editing for Sickle Cell Disea
- 597 (80-.). 110, 343–548 (1545).
598 9. Frangoul, H. *et al.* CRISPR-Cas
599 *Med.* 384, 252–260 (2021).
- 500 10. Simpson, S. Sickle cell disease: a new era. *Lancet Haematol.* 6, e393–e394 (2019).
501 11. Odame, I. Perspective: We need a global solution. Nature 515, S10–S10 (2014). med. 384, 232–260 (2021).
600 10. Simpson, S. Sickle cell disea.
601 11. Odame, I. Perspective: We r
-
- 600 10. Simpson, S. Sickle cell disease. a new era. Lancet Haemator. **o**, e393–e394 (2019).
601 11. Odame, I. Perspective: We need a global solution. Nature **515**, S10–S10 (2014).
602 12. Gyamfi, J. *et al.* Evidence-based 601 11. Odame, I. Perspective: We need a global solution. Nature 515, S10–S10 (2014).
602 12. Gyamfi, J. *et al.* Evidence-based interventions implemented in low-and middle-i
603 for sickle cell disease management: A syste 12. Gyamfi, J. *et al.* Evidence-based interventions implemented in low-and middle-income countri

for sickle cell disease management: A systematic review of randomized controlled trials. PLoS

One **16**, e0246700 (2021).

- Bain, B. J. Haemoglobinopathy Diagnosis. Haemoglobinopathy Diagnosis (Wiley, 2006). 605 13. Bain, B. J. Haemoglobinopen 605 13. Bain, B. J. Haemoglobinopathy Diagnosis. Haemoglobinopathy Diagnosis (Wiley, 2006).

medRxiv preprint doi: [https://doi.org/10.1101/2024.09.21.24314128;](https://doi.org/10.1101/2024.09.21.24314128) this version posted September 23, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

- 25. D'Costa, C. *et al.* Differential sensitivity to hypoxia enables shape-based classification of sickle cell
634 disease and trait blood samples at point of care. *Bioeng. Transl. Med.* 2020.10.28.20221358
635 (2023) doi
- disease and trait blood samples at point of care. *Bioeng. Transl. Med.* 2020.10.28.20221358
635 (2023) doi:10.1002/btm2.10643.
636 26. Li, H., Soto-Montoya, H., Voisin, M., Valenzuela, L. F. & Prakash, M. Octopi: Open con Free Construction (1999)
636 - 26. Li, H., Soto-Montoya, H., Voisin, N
637 - high-throughput imaging platforn
638 - doi:10.1101/684423. Fig. 26. Limitation of the Unity of the Units of the Units of the Units of the Units of the High-throughput imaging platform for infectious disease diagnosis in the field. *bioRxiv* (2019)
638 doi:10.1101/684423.
639 27. L
- figh-throughput maging platform for infectious disease diagnosis in the field. bioNArv (2015)
doi:10.1101/684423.
639 27. Li, H. *et al.* Squidⁿ: Simplifying Quantitative Imaging Platform Development and Deployment.
640 read of the 10.11012
640 (2020) doi:https://doi
641 - 28 - Li X, Dee M, Lyketry
- 640 (2020) doi:https://doi.org/10.1101/2020.12.28.424613.
641 28. Li, X., Dao, M., Lykotrafitis, G. & Karniadakis, G. E. Biomechanics and biorheology of red blood
642 cells in sickle cell anemia. *J. Biomech*. 50, 34–41 (2 641 (2021) doi:https://doi.org/2020-2020-2020-2020.
641 28. Li, X., Dao, M., Lykotrafitis, G. & Karniadakis, G. E. Biome
642 29. Barabine G. A. Blatt, M. O. & Kaul, D. K. Siekle Cell Biom
- 642 Collis in sickle cell anemia. J. Biomech. 50, 34–41 (2017).
643 29. Barabino, G. A., Platt, M. O. & Kaul, D. K. Sickle Cell Biomechanics. Annu. Rev. Biomed. Eng. 12,
644 345–367 (2010). 643 cells in sickle cell anemia. J. Biomech. 50, 34–41 (2017).
643 29. Barabino, G. A., Platt, M. O. & Kaul, D. K. Sickle Cell Bion
644 345–367 (2010).
- 29. Barabino, G. A., Platt, M. O. & Kaul, D. K. Sickle Cell Biomechanics. Annu. Rev. Biomed.

345–367 (2010).

645 30. Pachitariu, M. & Stringer, C. Cellpose 2.0: how to train your own model. Nat. Methods

2022.04.01.48676 111
645 30. Pachitariu, M. &
646 2022.04.01.4867
647 31 Shrotha B. et al.
- 646 30. Pachitariu, M. & Stringer, C. Celipose 2.0. how to train your own model. Nat. Methods
646 31. Shrestha, P. *et al.* erythroSight: Open-access image dataset of blood cells from individu
648 sickle cell disease and/o 647 31. Shrestha, P. *et al.* erythroSight: Open-access image dataset of
648 sickle cell disease and/or beta-thalassemia or without known
649 using automated microscope Octopi. *Federated Research Dat* 647 31. Shrestha, P. et al. erythrosight: Open-access image dataset of blood cells from individuals with
648 sickle cell disease and/or beta-thalassemia or without known hemaglobinopathies, captured
650 doi:10.20383/103.09 sickle cell disease and/or beta-thalassemia or without known hemaglobinopathies, c

using automated microscope Octopi. Federated Research Data Repository (2024)

doi:10.20383/103.0916.

651 32. Bain, B. J. Blood Cell Morph
- doi:10.20383/103.0916.
650 doi:10.20383/103.0916.
651 32. Bain, B. J. Blood Cell Morphology in Health and Disease. in *Dacie and Lewis Practic*
652 Haematology 61–92 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.00005-9 650 doi:10.20383/103.0916. 652 Bain, B. J. Blood Cell Morphology in Health and Disease. In Ducle and Lewis Practical
652 Haematology 61–92 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.00005-9.
653 33. Fawcett, T. An introduction to ROC analysis.
-
- Fraematology 61–92 (Elsevier, 2017). doi:10.1010/B978-0-7020-6696-2.00009-9.
653 33. Fawcett, T. An introduction to ROC analysis. Pattern Recognit. Lett. 27, 861–874 (
654 34. Ogunlade, B. et al. Predicting tuberculosis dr 653 33. Fawcett, T. An introduction to Roc analysis. Pattern Recognit. Lett. 27, 861–874 (2006).
654 34. Ogunlade, B. *et al.* Predicting tuberculosis drug resistance with machine learning-assiste
655 886 886 8861 8861 (20 954 34. Ogunlade, B. *et al.* Predicting tuberculosis drug resistance with machine learning-assisted Ramanus pectroscopy. (2023).
656 35. Roberts, M. *et al.* Common pitfalls and recommendations for using machine learning
- 656 35. Roberts, M. *et al.* Com
 657 and prognosticate for
 658 217 (2021). and prognosticate for COVID-19 using chest radiographs and CT scans. *Nat. Mach. Intell.* **3**, 199–
658. 217 (2021).
659. 86. Zhang, A., Xing, L., Zou, J. & Wu, J. C. Shifting machine learning for healthcare from developme
- Zhang, A., Xing, L., Zou, J. & Wu, J. C. Shifting machine learning for healthcare from development
24 659 36. Zhang, A., X $\begin{split} \mathcal{L}_{\mathcal{S}}(\mathcal{S}, \mathcal{S}, \mathcal{S}, \mathcal{S}) = \mathcal{S} = \mathcal{S}_{\mathcal{S}}(\mathcal{S}, \mathcal{S}) = \mathcal{S}_{\mathcal{S}}(\mathcal{S}, \mathcal$

- to deployment and from models to data. Nat. Biomed. Eng. (2022) doi:10.1038/s41551-022-
00898-y.
662 37. Shrestha, P. *et al.* Low-Cost Automated Microscopy and Morphology-Based Machine Learning
Classification of Sickle Ce 661 00898-y. Classification of Sickle Cell Disease and Beta-Thalassemia in Nepal and Canada. *Blood* **142**, 790–
664 790 (2023).
665 38. Shrestha. P. *et al.* Evaluation of Low-Cost Techniques to Detect Sickle Cell Disease and B-Classification of Sickle Cell Disease and Beta-Thalassemia in Nepal and Canada. Blood 142, 750–
664 790 (2023).
665 38. Shrestha, P. *et al.* Evaluation of Low-Cost Techniques to Detect Sickle Cell Disease and β-
666 Thal
-
- (1)
1955 665 788.
1966 7 667 (2024).
1967 1962 (2024). 665 36. Shrestha, P. et al. Evaluation of Low-Cost Techniques to Detect Sickle Cell Disease and β-
666 Thalassemia: An International Multi-Center Study. SSRN https://ssrn.com/abstract=4908
668 39. Valap Sealant. *Cold Spr* 11alassemia: An International Multi-Center Study. SSRN https://ssrn.com/abstract=4908786
667 (2024).
668 39. Valap Sealant. Cold Spring Harb. Protoc. 2015, pdb.rec082917 (2015).
-
- (2024).
668 39. Valap Se
669 40. Tian, L., 39. Valap Sealant. *Cold Spring Harb. Protoc.* **2015**, pdb.rec082917 (2015).
669 40. Tian, L., Wang, J. & Waller, L. 3D differential phase-contrast microscopy with computational
670 illumination using an LED array. *Opt. L*
- 670 1991 1992, Hang, J. March, L., W. L., M. Lett. 39, 1326 (2014).
671 41. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of Image Ana
672 HHS Public Access. Nat Methods 9, 671–675 (2012) 670 indimination using an LED array. Opt. Lett. 39, 1326 (2014).
671 41. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image
672 42. Schindelin J. et al. Fiji: An anen seurse platform for biologi
- 672 HHS Public Access. Nat Methods 9, 671–675 (2012).
673 42. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. Nat. Methods 9,
674 676–682 (2012). 672 HHS Public Access. Nat Methods 9, 671–675 (2012).
673 42. Schindelin, J. *et al.* Fiji: An open-source platform for
674 676–682 (2012). 42. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. Nat. Methods
674 676–682 (2012).
675 43. Lee, S. & Lee, D. K. What is the proper way to apply the multiple comparison test? Korean J.
- 675 43. Lee, S. & Lee, D. I
676 Anesthesiol. 71, 3
677 44 Memteri M. De
- 675 43. Lee, S. & Lee, D. K. What is the proper way to apply the multiple comparison test? Korean J. 678 $\,$ screening for β -thalassaemia trait? *J. Med. Screen.* **14**, 169–173 (2007).
679 678 screening for β-thalassaemia trait? *J. Med. Screen*. **14**, 169–173 (2007).
679 678 screening for β-thalassaemia trait? J. Med. Screen. 14, 169–173 (2007).
679

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

⁶⁸⁰**Figures and captions**

681

Fig. 1 | High-throughput imaging for morphology-based classification. a, Sequence of sample preparation, imaging, cell

segmentation, and classification. b, Computer-aided design (CAD) renderings of automated microscope, 687 homozygous sickle cell disease (SS = HbSS). Each image segment is 270 µm × 270 µm, cropped from 900 µm × 900 µm images
688 (original FOVs). Images were taken two hours after sample preparation for the sickling test (b 685 S1 in Supplementary information. c-g, Representative image segments from normal (AA = HbAA), β -thalassemia trait (ABeta = HbA/ β -thalassemia), sickle cell trait (AS = HbAS), compound heterozygous sickle cell dise 686 BHbA/β-thalassemia), sickle cell trait (AS = HbAS), compound heterozygous sickle cell disease (SBeta = HbS/β-thalassemia), and
687 hbA/β-thalassemia), sickle cell disease (SS = HbSS). Each image segment is 270 μm × 2 687 homozygous sickle cell disease (SS = HbSS). Each image segment is 270 μm × 270 μm, cropped from 900 μm × 900 μm images
688 (original FOVs). Images were taken two hours after sample preparation for the sickling test (For the cell disease (SS = Hall discussed cell discussed cell discussed cell and the sickling test (blood + 2% sodium metabisulphit in 1:2 volume ratio). White scale bars in images (a, c-g) are 100 µm. 689 in 1:2 volume ratio). White scale bars in images (a, c-g) are 100 μ m. 689 in 1:2 volume ratio). White scale bars in images (a, c-g) are 100 µm.

Fig. 2 | Morphological changes during sickling and examples of cells from different groups. a, Time series of image segments

for a sample from a sickle cell disease (HbSS) participant, showing sickling at the cellular le For a sample from a sinkle cell disease (Hackey, participant, original disease (Scale bars (white) are 50 pm
693 for a samplified from a sickling, respectively; Time interval between adjacent images is 75 seconds; Scale ba 694 b-g, Normalized frequency over time of different morphological parameters for an image (900 µm x 900 µm); Time series
695 includes 1000 instances (or curves of frequency distribution), for a total time period of 3000 s 695 includes 1000 instances (or curves of frequency distribution), for a total time period of 3000 seconds; Number of cells = 28
696 17 (mean ± standard deviation for 1000 instances); Morphological parameters changed betwe For the matter are included (or curves of frequency) includes the period of period of treatmental (yellow) and final (blue)

time instances with varying degrees for area (b), perimeter (c), major axis (d), minor axis (e), For the instances with varying degrees for area (b), perimeter (c), major axis (d), minor axis (e), roundness (f), and eccentricity (g).

Supplementary video 3 shows the sickling of RBCs over time at the image level at 120 698 Supplementary video 3 shows the sickling of RBCs over time at the image level at 120x speed. **h**, Examples of cells with different values of morphological parameters, arranged in descending order of roundness (Rnd), as Supplementary video 3 shows the sickling of RBCs over time at the image level at 120× speed. h, Examples of cells with different values of morphological parameters, arranged in descending order of roundness (Rnd), ascendin France of morphological parameters, and g arranged in descending order of roundness (Rnd), ascending order of roundating $\frac{1}{2}$, and not sorted for circularity (Circ); Scale bar (black) in the first image is 10 μ m 700 and not sorted for circularity (Circ); Scale bar (black) in the first image is 10 µm.

690

medRxiv preprint doi: [https://doi.org/10.1101/2024.09.21.24314128;](https://doi.org/10.1101/2024.09.21.24314128) this version posted September 23, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

702 Fig. 3 | Morphological characterization at different scales. a, Normalized frequency distribution of eccentricity for the different groups (AA, normal; ABeta, β-thalassemia trait; AS, sickle cell trait; SCD, sickle where each grey line represents aggregated results for all cells from each participant. **b**, Normalized frequency distribution of
 705 eccentricity at the coverslip level, where each grey lines represent aggregated resu For the cate of the coversily level, where each grey lines represent aggregated results for all cells in each coverslip. c,

706 normalized frequency distribution of eccentricity at the image level, where each grey line r 705 eccentricity at the coversing level, where each grey lines represent aggregated results for all cells in each towership. c,
705 normalized frequency distribution of eccentricity at the image level, where each grey lin The intermediate frequency distribution of the image level, where each group. The number of cells (N_{cells}) in each group are listed above all plots, while the number of donors (N_{donors}), coverslips ($N_{\text{coverslips}}$) and cells in each image. The colored lines (a-c) represent aggregated results for the entire group. The number of cells (N_{cells}) in each group. The number of cells (N_{cells}) in each group. The number of cells (N_{cells}) in group are listed above all plots, while the number of donors (Naology) coversings) and images (Nimages) are listed installed inside (Nimages).

709 the plots.

710
711
712
713
714 712 Fig. 4 | Statistical differences between frequency distributions of different groups at the coversing rever. a, p-values for
712 pairwise comparison of means of different groups at each bin using Scheffe's method, for

-
-
-
- 713 b, Normalized frequency distribution (30 bins) of major axis for different groups, corresponding to heatmap (in a). c, Box plot for major axis between 10.5 µm and 11 µm (highlighted by grey boxes in a and b), indicatin 2.13 b, Normalized frequency distribution (30 bins) of major axis for different groups, corresponding to heatmap (in a). c, Box plot for major axis between 10.5 μm and 11 μm (highlighted by grey boxes in a and b), indicat 715 for major axis between 10.5 µm and 11 µm (highlighted by grey boxes in a and b), indicating that there were significantly indice
 715 cells for SCD with major axis between 10.5 µm and 11 µm than the other groups. 715 cells for SCD with major axis between 10.5 µm and 11 µm than the other groups. d, Minimum overall p-values for all
combinations (grey boxes in a and b) shown as blue (filled) circles, and minimum p-values for each comb First combinations (grey boxes in a and b) shown as blue (filled) circles, and minimum p-values for each combination (green boxes in

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

217 and the system circles. E-h, Results for morphological parameter roundiness, with grey boxes (in e-hia) find data in gand in
219 corresponding to roundness values (e.g. grey boxes in a and e appear at the corresponding overall (geometric mean) p-values (e.g. grey boxes in a and e appear at the corresponding indices of 4 and 20). J. Minimum p-values for each combination of all morphological parameters (e.g. green boxes in a and e appear a values for each combination of all morphological parameters (e.g. green boxes in a and e appear at the corresponding indices

4 and 20). Orange in heatmaps (a, e, i, and j) indicates p value > 0.05 (difference not statisti 721 and 20). Orange in heatmaps (a, e, i, and j) indicates p value > 0.05 (difference not statistically significant), green boxes (in heatmaps) and green circles (d and h) indicate minimum p-values for the respective combi 121 4 and 20). Orange in heatmaps (a, e, i, and j) indicates p value > 0.05 (difference not statistically significant), green boxes (in heatmaps) and green circles (d and h) indicate minimum p-values for the respective com Featmaps) and green chees (d and h) indicate minimum p-values for the respective combination (row), and grey boxes (in

T23 heatmaps (i, j) indicate minimum overall (geometric mean) p-values for all 6 combinations. Red hor Fractings, and b and f) indicate minimum overall (geometric mean) p-values for all 6 combinations. Red horizontal mes in

724 heatmaps (i, j) indicate non-dimensional morphological parameters. Box plots show median (line), 724 heatmaps (i, j) indicate non-dimensional morphological parameters. Box plots show median (line), 25th and 75th percentiles

725 (box), non-outlier minimum and maximum (whiskers), and outliers (dots) for the normalized

Fig. 5 | Morphology based classification into different groups. a, Confusion matrix for classification into 3 groups (3Gp): AA & ABeta, AS, and SCD (SBeta and SS), where diagonal values represent percentages of correct represent misclassifications. Classifier: quadratic support vector machine (QSVM). **b**, Confusion matrix for classification into 3

groups suitable for screening both HbS and β -thalassemia (3GpSc): AA, trait conditions represent misclassifications. Classifier: quadratic support vector machine (QSVM). b, Confusion matrix for classification into 3

732 groups suitable for screening both HbS and β-thalassemia (3GpSc): AA, trait conditions 2732 groups suitable for screening both HbS and β-thalassemia (3GpSc): AA, trait conditions (ABeta and AS), SCD (SBeta and SS).

733 Classifier: QSVM. c, Confusion matrix for classification into 4 groups (4Gp): AA, ABeta, The subspace discriminant (SSD). Confusion matrices (a-c) are row-normalized. d-f, Receiver operating characteristic (ROC) c
for visualizing classifier performance at different thresholds, showing ROC curves for individual 735 for visualizing classifier performance at different thresholds, showing ROC curves for individual classes (one vs. all; colored
736 curves) and macro-averaged ROC curves (black curves) for all groups. Dashed diagonal l 736 curves) and macro-averaged ROC curves (black curves) for all groups. Dashed diagonal line (with AUC = 0.5) represents a 736 curves) and macro-averaged ROC curves (black curves) for all groups. Dashed diagonal line (with AUC = 0.5) represents a

-
-
- ROC curves show merged results (from 1000 iterations of randomized 80:20 participant-wise splits of training and testing data)
- random guessing classifier that cannot discriminate between positive and negative classes. The areas under the receiver

738 operating characteristic curve (AUC or AUROC) for individual and macro-averaged cases are shown.
-
-

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

-
- enticipant-wise splits. d-f, Heatmaps showing overall (or macro-averaged) and individual (one vs. all) metrics (AUC, sensitivity
and specificity) of the top 5 classifiers for 3 groups (AA & ABeta, AS, and SCD; purple uprig participant-wise splits. d-f, Heatmaps showing overall (or macro-averaged) and individual (one vs. all) metrics (AUC, sensitivity

and specificity) of the top 5 classifiers for 3 groups (AA & ABeta, AS, and SCD; purple upr
-
-
-
-
- 251 and specificity) of the top 5 classifiers for 3 groups (AA & ABeta, AS, and SCD; purple upright triangle; d), 3 groups for screening

252 (AA, trait, and SCD; orange inverted triangle; e), and 4 groups (AA, ABeta, AS, overall and individual metrics of the top 2 classifiers with different misclassification penalties (misclassifications of ABeta,

SCD as normal class AA had misclassification costs 10 times higher than for other misclassif
-
- 2022 overall and individual metrics of the top 2 classification costs 10 times higher than for other misclassifications) h, Heatmaps showing

253 overall and individual metrics of the top 2 classifiers with feature selecti overall and individual metrics of the top 2 classifiers with feature selection (77 top features selected from statistical analysis).

756 Abbreviations – AUC, Area under the receiver operating characteristic curve; Sens, S
-

760 Fig. 7 | Cost performance plot for different detection techniques. Comparison of different low-cost techniques, including
 761 conventional sickling test, solubility test, Sickle SCAN, HemoTypeSC, Gazelle Hb varia 121 conventional sickling test, solution, year, siems of this typeor, such as the relation of the automated const
1762 sickling test, against the reference test (Hb HPLC). Numbers indicate sensitivity (black) and specific techniques against reference test (Hb HPLC). Numbers for sensitivity and specificity for the automated sickling test is for

- 2764 detecting 3 groups (3*GpSc*) for screening HbS and β-thalassemia: normal (HbAA), triat (HbA/β-thalassemia & AS), and SCI
765 & HbS/β-thalassemia). 764 detecting 3 groups (3GpSc) for screening HbS and β-thalassemia. normal (HbAA), that (HbA/β-thalassemia & AS), and SCD (HbSS
765 & HbS/β-thalassemia).
- 755×10^{16}